<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pediatr</journal-id><journal-title-group><journal-title>BMC Pediatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2431</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22950861</article-id><article-id pub-id-type="pmc">3478965</article-id><article-id pub-id-type="publisher-id">1471-2431-12-144</article-id><article-id pub-id-type="doi">10.1186/1471-2431-12-144</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Filippi</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>l.filippi@meyer.it</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Fiorini</surname><given-names>Patrizio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>p.fiorini@meyer.it</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Daniotti</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>marta.daniotti@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Catarzi</surname><given-names>Serena</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.catarzi@libero.it</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Savelli</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>s.savelli@meyer.it</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Fonda</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>c.fonda@meyer.it</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Bartalena</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>l.bartalena@ao-pisa.toscana.it</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Boldrini</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>a.boldrini@clp.med.unipi.it</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Giampietri</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>giamping@gmail.com</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Scaramuzzo</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>rosa.scaramuzzo@gmail.com</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Papoff</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>p.papoff@libero.it</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Del Balzo</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>fdelbalzo@tiscali.it</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Spalice</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>a.spalice@tiscali.it</email></contrib><contrib contrib-type="author" id="A14"><name><surname>la Marca</surname><given-names>Giancarlo</given-names></name><xref ref-type="aff" rid="I7">7</xref><xref ref-type="aff" rid="I8">8</xref><email>g.lamarca@meyer.it</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Malvagia</surname><given-names>Sabrina</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>s.malvagia@meyer.it</email></contrib><contrib contrib-type="author" id="A16"><name><surname>Della Bona</surname><given-names>Maria Luisa</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>m.dellabona@meyer.it</email></contrib><contrib contrib-type="author" id="A17"><name><surname>Donzelli</surname><given-names>Gianpaolo</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>donzelli@unifi.it</email></contrib><contrib contrib-type="author" id="A18"><name><surname>Tinelli</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>francesca.tinelli@inpe.unipi.it</email></contrib><contrib contrib-type="author" id="A19"><name><surname>Cioni</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>gcioni@inpe.unipi.it</email></contrib><contrib contrib-type="author" id="A20"><name><surname>Pisano</surname><given-names>Tiziana</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>t.pisano@meyer.it</email></contrib><contrib contrib-type="author" id="A21"><name><surname>Falchi</surname><given-names>Melania</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>m.falchi@meyer.it</email></contrib><contrib contrib-type="author" id="A22"><name><surname>Guerrini</surname><given-names>Renzo</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>r.guerrini@meyer.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Neonatal Intensive Care Unit, Medical Surgical Feto-Neonatal Department, &#x0201c;A. Meyer&#x0201d; University Children&#x02019;s Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy</aff><aff id="I2"><label>2</label>Department of Radiological Sciences, &#x0201c;A. Meyer&#x0201d; University Children's Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy</aff><aff id="I3"><label>3</label>Neonatal Unit, University of Pisa, Via Roma, 67, I-56126, Pisa, Italy</aff><aff id="I4"><label>4</label>Istituto di Scienze della Vita, Scuola Superiore Sant&#x02019;Anna, Piazza Martiri della Libert&#x000e0;, 33, I-56127, Pisa, Italy</aff><aff id="I5"><label>5</label>Pediatric Emergency and Intensive Care, Department of Pediatrics, La Sapienza University of Rome, Viale del Policlinico, 155, I-00186, Rome, Italy</aff><aff id="I6"><label>6</label>Division of Child Neurology, Department of Pediatrics, La Sapienza University of Rome, Viale del Policlinico, 155, I-00186, Rome, Italy</aff><aff id="I7"><label>7</label>Department of Pharmacology, University of Florence, Viale Pieraccini, 6, I-50139, Florence, Italy</aff><aff id="I8"><label>8</label>Laboratory for diseases of the nervous system and metabolism, &#x0201c;A. Meyer&#x0201d; University Children&#x02019;s Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy</aff><aff id="I9"><label>9</label>Department of Sciences for Woman and Child's Health, University of Florence, &#x0201c;A. Meyer&#x0201d; Children's Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy</aff><aff id="I10"><label>10</label>Department of Developmental Neuroscience, Stella Maris Scientific Institute, Viale del Tirreno, 331, I-56128, Calambrone, Pisa, Italy</aff><aff id="I11"><label>11</label>Paediatric Neurology Unit and Laboratories, &#x0201c;A. Meyer&#x0201d; Children&#x02019;s Hospital, University of Florence, Viale Pieraccini, 24, I-50139, Florence, Italy</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>5</day><month>9</month><year>2012</year></pub-date><volume>12</volume><fpage>144</fpage><lpage>144</lpage><history><date date-type="received"><day>22</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Filippi et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Filippi et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2431/12/144"/><abstract><sec><title>Background</title><p>Despite progresses in neonatal care, the mortality and the incidence of neuro-motor disability after perinatal asphyxia have failed to show substantial improvements. In countries with a high level of perinatal care, the incidence of asphyxia responsible for moderate or severe encephalopathy is still 2&#x02013;3 per 1000 term newborns. Recent trials have demonstrated that moderate hypothermia, started within 6 hours after birth and protracted for 72 hours, can significantly improve survival and reduce neurologic impairment in neonates with hypoxic-ischemic encephalopathy. It is not currently known whether neuroprotective drugs can further improve the beneficial effects of hypothermia. Topiramate has been proven to reduce brain injury in animal models of neonatal hypoxic ischemic encephalopathy. However, the association of mild hypothermia and topiramate treatment has never been studied in human newborns. The objective of this research project is to evaluate, through a multicenter randomized controlled trial, whether the efficacy of moderate hypothermia can be increased by concomitant topiramate treatment.</p></sec><sec><title>Methods/Design</title><p>Term newborns (gestational age &#x02265; 36 weeks and birth weight &#x02265; 1800 g) with precocious metabolic, clinical and electroencephalographic (EEG) signs of hypoxic-ischemic encephalopathy will be randomized, according to their EEG pattern, to receive topiramate added to standard treatment with moderate hypothermia or standard treatment alone. Topiramate will be administered at 10 mg/kg once a day for the first 3 days of life. Topiramate concentrations will be measured on serial dried blood spots. 64 participants will be recruited in the study. To evaluate the safety of topiramate administration, cardiac and respiratory parameters will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance. To evaluate the efficacy of topiramate, the neurologic outcome of enrolled newborns will be evaluated by serial neurologic and neuroradiologic examinations. Visual function will be evaluated by means of behavioural standardized tests.</p></sec><sec><title>Discussion</title><p>This pilot study will explore the possible therapeutic role of topiramate in combination with moderate hypothermia. Any favourable results of this research might open new perspectives about the reduction of cerebral damage in asphyxiated newborns.</p></sec><sec><title>Trial registration</title><p>Current Controlled Trials ISRCTN62175998; ClinicalTrials.gov Identifier NCT01241019; EudraCT Number 2010-018627-25</p></sec></abstract><kwd-group><kwd>Neonatal hypoxic-ischemic encephalopathy</kwd><kwd>Therapeutic hypothermia</kwd><kwd>Topiramate</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><sec><title>Neonatal hypoxic-ischemic encephalopathy: disease incidence and pathogenesis</title><p>In countries with a high level of perinatal care, the incidence of asphyxia responsible for moderate or severe encephalopathy is 2&#x02013;3 per 1000 term infants
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The ensuing encephalopathy may present with need for resuscitation at birth, neurological depression, seizures or electroencephalographic (EEG) abnormalities. Hypoxic ischemic encephalopathy (HIE) is still the leading cause of perinatal mortality and severe neurological impairment. Mortality rate is 10% for moderate and 60% for severe HIE. About 30% of survivors with moderate and 100% with severe HIE exhibit permanent neurological disability
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Encephalopathy results from the combination of reduced cerebral oxygenation (hypoxemia) and/or reduced perfusion (ischemia). Cerebral damage develops in two distinct phases. During the acute phase neuronal death occurs by necrosis of neuronal cells, a result of a rapid depletion of brain energy. However, after a few hours, cerebral energy metabolism recovers, but a cascading series of biochemical events triggers neuronal apoptosis and leads to severe brain damage. These events include an increased release of excitatory neurotransmitters, especially glutamate
[<xref ref-type="bibr" rid="B5">5</xref>]. Glutamate acts on three classes of receptors that control the passage of ion channels through the neural cell membrane: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate and <italic>N</italic>-methyl-D-aspartate (NMDA) receptors. Neurons (and glia) contain high concentrations of glutamate, which is usually released in small amounts and for short periods of time (milliseconds)
[<xref ref-type="bibr" rid="B6">6</xref>]. Exceedingly high glutamate concentrations can over-excite nervous cells and lead to their death (excito-toxicity)
[<xref ref-type="bibr" rid="B7">7</xref>]. This excito-toxicity contributes to neuronal damage in various neurodegenerative disorders.</p><p>Glutamate activates AMPA receptors, depolarizes the cell and promotes the removal of the voltage-dependent block operated by Mg<sup>++</sup>[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>] on NMDA receptors: this promotes the entry of Ca<sup>++</sup> through this channel
[<xref ref-type="bibr" rid="B10">10</xref>]. Calcium entry stimulates in turn a series of processes that lead to necrosis and apoptosis. These processes include the Ca<sup>++</sup> overload in the mitochondria, responsible for the production of free radicals
[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]; the activation of caspases and the release of factors inducing apoptosis
[<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>]; the activation of a neuronal nitric oxide synthase (nNOS) that triggers the synthesis of nitric oxide (NO) and the formation of toxic peroxynitrite and nitrosylated-GAPDH; the stimulation of p38 mitogen-activated protein kinase (p38 MAPK), which activates the transcription of factors that enter the nucleus and promote neuronal damage and apoptosis
[<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Between the acute initial damage and the ensuing damage mediated by the release of toxic substances, there is therefore a time window that could offer the possibility of a combined neuroprotective treatment.</p></sec><sec><title>Hypothermia as a neuroprotective treatment in animals</title><p>Currently the most effective neuroprotective intervention for asphyxiated infants is treatment with moderate hypothermia, a reduction in body temperature of 3-4&#x000b0;C. Experimental studies performed in adult and newborn animals have shown that reducing brain temperature by 2-4&#x000b0;C after ischemia protects the brain from neuronal damage and cell death and improves neurological
[<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref>] and behavioral outcome, as well as histological changes
[<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Several mechanisms may explain these benefits: hypothermia reduces the accumulation of extracellular glutamate, enhancing post-ischemic glutamate re-uptake
[<xref ref-type="bibr" rid="B30">30</xref>], the synthesis of free radicals and nitric oxide
[<xref ref-type="bibr" rid="B15">15</xref>], preserves the content of high-caloric cerebral phosphates, reduces cerebral alkalosis and lactate levels
[<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Hypothermia may also suppress the activation of microglia
[<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. These actions can preserve brain energy metabolism, reduce cytotoxic cerebral edema and inhibit neuronal death. Thanks to animal experiments, the optimal temperature for brain neuroprotection, leading to reduce biochemical and histological markers of neuronal damage, has been observed to be between 32 and 34&#x000b0;C
[<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. Most of these studies indicate that hypothermic treatment should be immediate or precocious (within 6 hours from the insult), while neuroprotection diminishes or disappears if the cooling is delayed beyond 6 hours
[<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. For this reason, hypothermic treatment following asphyxia should be initiated as soon as possible. The duration of treatment with hypothermia varied in such experimental studies. Significant benefits were obtained when moderate hypothermia was maintained for at least 12&#x02013;24 hours, but it has been suggested that more prolonged treatment, up to 72 hours
[<xref ref-type="bibr" rid="B42">42</xref>], may be necessary if the interval before induction of hypothermia is prolonged
[<xref ref-type="bibr" rid="B43">43</xref>]. In sheep fetuses a rebound of epileptic activity has been reported after rapid heating
[<xref ref-type="bibr" rid="B43">43</xref>]. Finally, hypothermia appears to be more neuroprotective in animal exposed to moderate, rather than severe asphyxia
[<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B44">44</xref>].</p><p>In conclusion, there is a strong experimental evidence that moderate hypothermia in asphyxiated animals produces behavioral and histological benefits both in the short-term
[<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B45">45</xref>], and in the long-term
[<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B49">49</xref>].</p></sec><sec><title>Hypothermia as a neuroprotective treatment in human neonates</title><p>In human neonates hypothermia has been described for the first time as a treatment for resuscitation in the '60s, before modern techniques of resuscitation were introduced
[<xref ref-type="bibr" rid="B50">50</xref>]. In such occasions, hypothermia was used only for short periods of time after failed resuscitation, but details regarding side-effects or clinical long-term outcome of these infants were not provided
[<xref ref-type="bibr" rid="B51">51</xref>-<xref ref-type="bibr" rid="B55">55</xref>]. Since the late '90s, on the basis of the above mentioned animal studies, pilot studies with selective brain hypothermia associated with generalized mild hypothermia or generalized moderate hypothermia between 35.5 and 33.0&#x000b0;C for 48&#x02013;72 hours, have been performed in infants with HIE demonstrating the feasibility of this treatment in term infants
[<xref ref-type="bibr" rid="B56">56</xref>-<xref ref-type="bibr" rid="B62">62</xref>]. In the early 2000, the first cases reports showed better neurodevelopmental outcomes in cooled asphyxiated infants: whole-body hypothermia was observed to reduce the damage of thalami, basal ganglia, and white matter, while selective brain hypothermia appeared to be more effective in protecting the cortex
[<xref ref-type="bibr" rid="B63">63</xref>-<xref ref-type="bibr" rid="B65">65</xref>].</p><p>So far, seven randomized controlled trials regarding the efficacy of therapeutic hypothermia for the treatment of neonatal encephalopathy have been published
[<xref ref-type="bibr" rid="B66">66</xref>-<xref ref-type="bibr" rid="B72">72</xref>]. Two such trials adopted the selective cerebral hypothermia
[<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B72">72</xref>] and five the total-body hypothermia
[<xref ref-type="bibr" rid="B67">67</xref>-<xref ref-type="bibr" rid="B71">71</xref>]. All of these trials, powered to detect a difference in the primary composite outcome of death and/or disability, demonstrated the benefits of hypothermia. A meta-analysis of the first trials showed that moderate hypothermia reduced death or disability at 18 months with a risk ratio of 0.81 (95% CI, 0.71-0.93) and a number needed to treat (NNT) of 9
[<xref ref-type="bibr" rid="B73">73</xref>]. The first data from follow-up of newborns enrolled in the CoolCap Trial and NICHD Trial showed that neurodevelopmental outcomes calculated at 18&#x02013;22 months of life predicted the functional outcomes into childhood
[<xref ref-type="bibr" rid="B74">74</xref>,<xref ref-type="bibr" rid="B75">75</xref>].</p><p>Overall, if the small study of Eicher is excluded
[<xref ref-type="bibr" rid="B76">76</xref>], major trials suggest that cooling is a safe procedure in newborns. Recent reviews concluded that bradycardia and thrombocytopenia were the only clinical, though benign, adverse effects that were more common with hypothermia
[<xref ref-type="bibr" rid="B77">77</xref>-<xref ref-type="bibr" rid="B79">79</xref>]. Therapeutic hypothermia has recently been included in the Guidelines of International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science and in the recommendations of the American Heart Association
[<xref ref-type="bibr" rid="B80">80</xref>,<xref ref-type="bibr" rid="B81">81</xref>].</p><p>Neuroprotective drugs may enhance the efficacy of hypothermia for the treatment of neonatal HIE
[<xref ref-type="bibr" rid="B82">82</xref>]. However, there are no studies that have explored the combined treatment with hypothermia and topiramate in asphyxiated newborns.</p></sec><sec><title>Topiramate</title><p>Topiramate (TPM) is an anticonvulsant agent widely used in adults and children, characterized by good absorption, high bioavailability, and good tolerability
[<xref ref-type="bibr" rid="B83">83</xref>]. TPM has multiple mechanisms of action, including glutamate-receptors inhibition
[<xref ref-type="bibr" rid="B83">83</xref>,<xref ref-type="bibr" rid="B84">84</xref>], which implies a potential as neuroprotective agent. TPM did indeed demonstrate neuroprotective properties against hypoxic ischemic brain damage, both <italic>in vitro</italic> and in animal models, and was recently proposed as an innovative neuroprotective therapy for ischemic stroke
[<xref ref-type="bibr" rid="B85">85</xref>-<xref ref-type="bibr" rid="B92">92</xref>] and neonatal hypoxic-ischemic cerebral injury
[<xref ref-type="bibr" rid="B93">93</xref>]. In neuronal cultures, cell damage induced by oxygen-glucose deprivation
[<xref ref-type="bibr" rid="B91">91</xref>] or excitotoxic glutamate or kainate concentrations
[<xref ref-type="bibr" rid="B94">94</xref>], was consistently attenuated by TPM. In animal models of transient global cerebral ischemia intravenous, intraperitoneal, or oral TPM reduced the severity of cerebral damage either alone
[<xref ref-type="bibr" rid="B86">86</xref>-<xref ref-type="bibr" rid="B89">89</xref>] or with hypothermia
[<xref ref-type="bibr" rid="B90">90</xref>] in a dose-dependent manner, with neuroprotective doses ranging from 5&#x02013;200 mg/kg, usually in single administration
[<xref ref-type="bibr" rid="B87">87</xref>-<xref ref-type="bibr" rid="B91">91</xref>]. TPM was also demonstrated to exert neuroprotective effects against periventricular leukomalacia
[<xref ref-type="bibr" rid="B92">92</xref>].</p><p>The neuroprotective mechanisms of TPM appear to be related not only to AMPA and kainate receptors inhibition
[<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B94">94</xref>-<xref ref-type="bibr" rid="B97">97</xref>], but also to blockade of Na<sup>+</sup> channels
[<xref ref-type="bibr" rid="B98">98</xref>], high voltage-activated calcium currents
[<xref ref-type="bibr" rid="B85">85</xref>], carbonic anhydrase isoenzymes
[<xref ref-type="bibr" rid="B99">99</xref>], and mitochondrial permeability transition pore (MPTP)
[<xref ref-type="bibr" rid="B100">100</xref>].</p><p>To date, no clinical study has been published to prove an additive or synergistic action of TPM combined with hypothermia in newborns with HIE.</p><p>We previously reported that TPM pharmacokinetic properties at the dose of 5 mg/kg appear to be modified by concomitant hypothermia
[<xref ref-type="bibr" rid="B101">101</xref>]. Likewise observed with other poorly metabolized drugs
[<xref ref-type="bibr" rid="B102">102</xref>], hypothermia reduces TPM clearance and slows absorption and elimination processes
[<xref ref-type="bibr" rid="B103">103</xref>].</p><p>Although long-term effects on cognitive functions of TPM administration in early life remain to be assessed, short-term safety is reassuring enough to support its evaluation in clinical trials that explore its possible additive neuroprotective action
[<xref ref-type="bibr" rid="B104">104</xref>]. The gap between effective and neurotoxic doses is greater for TPM than for other antiepileptic drugs
[<xref ref-type="bibr" rid="B103">103</xref>], and short-course therapy appears to have few neurotoxic effects. Regarding TPM long-term effects, in asphyxiated animal models treated with TPM, no cognitive deficit was demonstrated
[<xref ref-type="bibr" rid="B91">91</xref>], and in epileptic neonate rodents, TPM was safer than phenobarbital or benzodiazepines
[<xref ref-type="bibr" rid="B103">103</xref>,<xref ref-type="bibr" rid="B105">105</xref>]. Neuronal death occurred at doses of 50 mg/kg, which are considerably higher than doses used in common therapeutic schedules.</p></sec><sec><title>Hypothesis</title><p>In conclusion, several <italic>in vitro</italic> and <italic>in vivo</italic> experimental studies have demonstrated that both, hypothermia and TPM, are able to reduce post-ischemic neuronal damage. So far no study has investigated whether the combined action of these procedures may be additive to their individual neuroprotective potential. We hypothesize that the combination treatment with moderate whole-body hypothermia associated with TPM administration is safe and enhances the neuroprotective properties of hypothermia for the treatment of neonatal HIE.</p></sec><sec><title>Objectives</title><sec><title>Major objectives: safety and efficacy of TPM associated with moderate whole-body hypothermia</title><p>The first purpose of this study is to confirm the safety of TPM administration in asphyxiated newborns. For this purpose, cardiac and respiratory parameters (heart frequency, blood pressure, oxygen saturation, respiratory support), will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance.</p><p>TPM is considered to be safe and generally well tolerated in children. The safety profile of TPM might be different in neonates with HIE treated with hypothermia than in adults receiving chronic therapy for epilepsy. TPM can cause metabolic acidosis, especially in pediatric patients, because of carbonic anhydrase inhibition at proximal renal tubule with consequent renal loss of bicarbonate
[<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B107">107</xref>]. In as many as 48% of adults and 67% of children with epilepsy treated with TPM, a variable degree of metabolic acidosis develops. However, in most reported cases, bicarbonate levels did not decrease to be clinically significant. Only 11% of patients had serum bicarbonate levels &#x0003c;17 mEq/L
[<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B108">108</xref>] and symptomatic cases were successfully treated with sodium bicarbonate supplementation
[<xref ref-type="bibr" rid="B106">106</xref>]. Although this observation is reassuring, metabolic acidosis is usually severe in neonates with HIE, who have metabolic acidosis because of both asphyxia and renal impairment. In infants, metabolic acidosis usually occurs after 8 to 26 days of TPM treatment, with dosages as high as 8.2 to 26 mg/kg/day
[<xref ref-type="bibr" rid="B109">109</xref>]. Similar to other carbonic acid anhydrase inhibitors, long-course TPM therapy is associated with increased risk of nephrolithiasis in adults
[<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B107">107</xref>]. Angle closure glaucoma and acute myopia are additional, though potentially reversible, adverse events related to TPM treatment in the pediatric age
[<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B107">107</xref>,<xref ref-type="bibr" rid="B110">110</xref>]. In a safety study, we found no signs of metabolic acidosis in newborns co-treated with moderate hypothermia and TPM; abdomen ultrasound scanning did not show kidney stones and ophthalmological evaluation was normal in all treated newborns
[<xref ref-type="bibr" rid="B104">104</xref>].</p><p>The second objective of this study is to evaluate the efficacy of TPM add-on therapy, evaluating the clinical outcome of enrolled newborns. The neurological and neuroradiologic outcome of newborns treated with hypothermia plus TPM will be compared to the outcome of control group that received hypothermia alone.</p></sec></sec></sec><sec><title>Methods/Design</title><sec><title>Study population-setting</title><p>Term newborns delivered at gestational age higher than 36 weeks and with birth weight higher than 1800 g admitted for HIE to the Neonatal Intensive Care Units (NICUs) of A. Meyer University Children&#x02019;s Hospital, Florence, of the Santa Chiara University Hospital of Pisa and of the La Sapienza University of Rome.</p></sec><sec><title>Study design</title><p>Multicenter interventional pilot randomized controlled trial to compare the safety and efficacy of TPM add-on therapy associated to the conventional approach (treatment with whole-body moderate hypothermia).</p><sec><title>Hypothermia</title><p>All newborns who will satisfy admission criteria will be treated with moderate (33.5&#x000b0;C) hypothermia for 72 hours. Outborn patients will be initially cooled to 35&#x000b0;C at the birth hospital, avoiding heating and using ice packs during the transfer to NICU. In all the centers a cooling blanket with an esophageal probe will be used to induce hypothermia; the esophageal temperature will be lowered by the blanket&#x02019;s servomechanism. Rectal temperature will be monitored by a rectal probe connected to cardiomonitor. After 72 hours of hypothermia, all newborns will be gradually re-warmed up to 36.5-37&#x000b0;C over the following 6&#x02013;12 hours (0.5&#x000b0;C/h). Vital parameters will be continuously monitored under hypothermia.</p><p>Half of these newborns will be subjected to additional treatment with oral topiramate.</p></sec><sec><title>Topiramate</title><p>TPM (Topamax, Janssen-Cilag, Cologno Monzese, Milan, Italy) will be administered by orogastric tube as enteric-coated granules mixed with water at the beginning of hypothermia for the first three days of life, for a total amount of 3 doses per patient. Newborns will receive 10 mg/kg once a day, a dosage usually used in infants
[<xref ref-type="bibr" rid="B111">111</xref>-<xref ref-type="bibr" rid="B113">113</xref>] and neonates
[<xref ref-type="bibr" rid="B114">114</xref>-<xref ref-type="bibr" rid="B117">117</xref>]. TPM plasma concentrations will be measured as previously reported
[<xref ref-type="bibr" rid="B118">118</xref>].</p></sec><sec><title>Monitoring</title><p>The following respiratory and hemodynamic parameters will be registered before starting hypothermia and then at hours 0, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 of hypothermia, and after the re-warming process: respiratory rate, oxygen saturation (SaO<sub>2</sub>), fractional inspired oxygen (FiO<sub>2</sub>), systolic, diastolic and mean arterial pressures, heart rate. The following blood tests will be performed in all newborns at hypothermia hours 0, 24, 48, 72 and after re-warming process: blood gas analysis (corrected for body temperature), serum electrolytes, liver and renal function tests, creatine-kinase, creatine-kinase MB isoenzyme, lactate dehydrogenase, troponin IC, complete cell blood count, C-reactive protein, procalcitonin and coagulation tests.</p></sec><sec><title>Clinical course and concomitant treatments</title><p>A central venous line will be placed in all patients. Fluid intake will be started at 60&#x02013;70 mL/kg and increased of 10&#x02013;20 mL/kg each day, basing on changes in body weight and serum electrolytes levels. Minimal enteral feeding will be allowed with human milk from the first day of life. In case of respiratory failure newborns will be put on patient triggered ventilation. Neonates who will develop seizures will be treated with phenobarbital, (loading dose 20 mg/kg, followed by 1.5-2.5 mg/kg every 12 hours). In case of resistance to phenobarbital, midazolam will be used with a dose-initial bolus of 0.15 mg/kg, followed by a continuous infusion (1 &#x003bc;g/kg/min) increased by 0.5-1 &#x003bc;g/kg/min every 2 minutes until a favourable response and up to a maximum dose of 18 &#x003bc;g/kg/min
[<xref ref-type="bibr" rid="B117">117</xref>]. In case of hypotension, defined as a mean arterial blood pressure &#x0003c;40 mmHg, single or multiple normal saline boluses will be administered (10&#x02013;20 mL/kg), and in case of refractoriness, dopamine, dobutamine, norepinephrine or terlipressin
[<xref ref-type="bibr" rid="B119">119</xref>] will be progressively added. Newborns will receive analgesia with Fentanyl at a dose of 1 &#x003bc;g/kg/h, since hypothermia causes agitation and reducing the threshold of pain.</p></sec></sec><sec><title>Neurological follow-up</title><p>The duration of follow-up necessary for possible neuro-motor disabilities and cognitive loss will be 24 months.</p><p>Every newborn will be evaluated beyond the neonatal period, at 1, 3, 6, 12, 18 and 24 months of life. Standard EEG will be evaluated within one week and will be repeated if abnormal. Within the first week and three months of age, newborns will be studied with Neonatal Hammersmith neurological examination and General Movement (GMs) assessment
[<xref ref-type="bibr" rid="B120">120</xref>]. The Hammersmith Infant Neurological Examination
[<xref ref-type="bibr" rid="B121">121</xref>,<xref ref-type="bibr" rid="B122">122</xref>] will be performed between 3 and 6 months of life. The mental and motor development will be evaluated with the Bayley Scales of Infant and Toddler Development 3<sup>rd</sup> edition
[<xref ref-type="bibr" rid="B123">123</xref>] measure at 12, 18 and 24 months. Bayley scales will be used to measure the major areas of development: cognitive, language, motor, social-emotional and adaptive functioning.</p><p>Visual function will be assessed in the first ten days of life by means of a recently published battery of behavioural tests designed to assess various aspects of visual function
[<xref ref-type="bibr" rid="B124">124</xref>,<xref ref-type="bibr" rid="B125">125</xref>], which includes items that assess ocular movements (spontaneous behaviour and in response to a target), the ability to fix and follow a black/white target (horizontally, vertically, and in an arc), the reaction to a colored target, the ability to discriminate between black and white stripes of increasing spatial frequency, and the ability to keep attention on a target that is moved slowly away from the infant. Visual function will be evaluated again at 4 &#x000bd;, 6 and 12 months with particular regards to binocular visual acuity, measured by means of standardized instruments based on preferential force choice (Teller acuity cards), stereopsis and ocular motricity.</p><p>Acoustic function will be monitored until 24 months.</p><p>Neurologists responsible of clinical follow-up will be blindfolded about which newborns have been treated with TPM in addition to hypothermia.</p><sec><title>Neuroradiologic follow-up</title><p>Standard cerebral magnetic resonance imaging (MRI), diffusion tensor imaging (DTI) and spectroscopy will be performed at the end of the hypothermic treatment within the first week, at three months and at 18 months.</p><p>Neuroradiologists responsible of follow-up will be blindfolded about which newborns have been treated with TPM in addition to hypothermia.</p></sec></sec><sec><title>Inclusion criteria</title><p>The treatment with therapeutic hypothermia will be reserved to newborns with gestational age &#x02265; 36 weeks and birth weight &#x02265; 1,800 g who will fulfill the following criteria:</p><p>1. Metabolic criteria: Apgar score &#x02264;5 at 10 min, or persisting need for resuscitation, including endotracheal intubation or mask ventilation for more than 10 min after birth, or acidosis (pH &#x02264;7.0 and/or base deficit &#x02265; &#x02212;16 mmol/L in umbilical cord blood or arterial, venous, or capillary blood) within 60 min from birth;</p><p>2. Neurological criteria (modified from Sarnat and Sarnat
[<xref ref-type="bibr" rid="B126">126</xref>]): moderate to severe encephalopathy consisting of altered state of consciousness (irritability, lethargy, stupor, or coma) and &#x02265; 1 of the following signs: hypotonia, or abnormal reflexes including oculomotor or pupil abnormalities, or absent or weak suctioning, or clinical seizures;</p><p>3. aEEG criteria: &#x0201c;moderately abnormal&#x0201d; indicates a background tracing with upper margin &#x0003e;10 &#x003bc;V and lower margin &#x02264;5 &#x003bc;V; &#x0201c;severely abnormal&#x0201d; pattern refers to a tracing with upper margin &#x0003c;10 &#x003bc;V and lower margin &#x0003c;5 &#x003bc;V; often this is accompanied by bursts of high voltage activity (&#x0201c;burst suppression&#x0201d;). Seizures are identified as periods of sudden increase in voltage, accompanied by narrowing of the band of aEEG activity followed by a brief period of suppression or by a build up of rhythmic activity of increasing amplitude and decreasing frequency
[<xref ref-type="bibr" rid="B127">127</xref>].</p></sec><sec><title>Selection criteria for study subjects</title><p>At least one of the parents of the newborns meeting the inclusion criteria will be approached by the study investigator/nurse and informed of the study. A signed parental informed consent must be obtained.</p></sec><sec><title>Exclusion criteria</title><p>1. Newborns with gestational age less than 36 weeks, with birth weights less than 1800 g, or admitted at the NICU after 6 hours of life.</p><p>2. Newborns with major congenital abnormalities or other syndromes that include brain malformations, congenital viral infections or evidence encephalopathy other than HIE.</p><p>3. Informed Consent refused.</p></sec><sec><title>Allocation of participants to the trial groups (Randomization)</title><p>EEG is useful in identifying suitable newborns for hypothermia due to its capability to distinguish newborns with Sarnat grade 2 from those with Sarnat 1. Several studies have demonstrated that aEEG is easier to be interpreted than standard EEG, but equally accurate and reproducible. It correlates well with neurodevelopmental outcome of full-term infants with HIE, and it is considered the best single predictor of neurologic outcome. In some studies aEEG was more specific and exhibited a higher positive predictive value when compared with the neurologic examination performed in the first hours after delivery
[<xref ref-type="bibr" rid="B128">128</xref>-<xref ref-type="bibr" rid="B131">131</xref>].</p><p>In all three recruiting hospitals, randomization will be done stratifying eligible newborns according to aEEG into moderate or severe HIE. Newborns will be assigned to the group of moderate or severe aEEG to ensure maximal clinical homogeneity between the groups.</p><p>Newborns will be randomized in blocks of eight for each group, alternating newborns between TPM added to standard hypothermic treatment and standard treatment alone.</p></sec><sec><title>Experimental plan and data analysis</title><p>Based on the medical literature, the mean incidence of the combined frequency of mortality and severe neurodevelopmental disability in survivors at 18 months of age is approximately 50%. In fact this percentage is 55% in the cool Cap study
[<xref ref-type="bibr" rid="B66">66</xref>], 44% in the NICHD study
[<xref ref-type="bibr" rid="B68">68</xref>], 45% in the TOBY trial
[<xref ref-type="bibr" rid="B69">69</xref>], 51.4% in the ICE trial
[<xref ref-type="bibr" rid="B70">70</xref>], and 50.9% in the neo.nEURO.network study
[<xref ref-type="bibr" rid="B71">71</xref>]. We hypothesize that treatment with TPM may reduce the incidence of the combined frequency of mortality and severe neurodevelopmental disability in survivors at 18 months at 15%. In order to compare the incidence of this primary outcome between newborns receiving TPM plus hypothermia (treated) and those only receiving hypothermia (control group), the estimated sample size was calculated, considering normal distribution, an alpha error of 0.05 and a power of 80 percent. The sample size for each group is 32 participants.</p><p>The three units have an overall admission rate of approximately 10 term newborns with HIE per year. Due to the high hypothetical advantages of this treatment, we estimate 90-100% rate of consent and we predict we would recruit the 64 newborns over around 24 months period with a realistic safety margin.</p><p>Mortality, the incidence of severe neuromotor disability, cortical vision, sensorineural hearing loss, developmental delay, epilepsy will be evaluated at 18 months of life.</p><p>To evaluate TPM safety, cardiac and respiratory parameters (heart frequency, blood pressure, oxygen saturation, respiratory support), will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance. Kruskal-Wallis test will be used to assess possible differences between newborns treated or not with TPM. The safety will be also evaluated by means of relative risk (RR)
[<xref ref-type="bibr" rid="B132">132</xref>]. RR will be calculated as the ratio between the probabilities of side effects in the TPM group with respect to the control group. Values of RR lower than 1, will be associated to the efficacy of the treatment.</p><p>Finally, we will evaluate the different distribution of any brain lesions on MRI brain highlighted.The RR is calculated for each item studied. An RR &#x0003c;1 indicates an improvement of neurological, neurodevelopmental and neuroradiologic hypothermia due to the association-topiramate.</p></sec><sec><title>Primary outcome</title><p>The neurological and neuroimaging outcome of these two groups of infants will be compared to determine whether adjunctive treatment with TPM improves the neuroprotective effect of hypothermic treatment.</p><p>The primary outcome will be the combined frequency of mortality and severe neurodevelopmental disability in survivors at 24 months of age. Severe disability is defined as Bayley III
[<xref ref-type="bibr" rid="B123">123</xref>] cognitive development index 3 SDs below mean or any one of the components of severe sensorimotor disability (e.g. inability to walk, sit, feed using hands, communicate (Bayley III language development index 3 SDs below mean), hear (80 dB sensory neural hearing loss) or see.</p></sec><sec><title>Secondary outcomes</title><p>The following secondary outcomes will also be assessed at 24 months of life:</p><p>&#x02022;Multiorgan dysfunction (adverse events in three or more organ systems),</p><p>&#x02022;Bilateral sensorineural hearing loss more than 40 dB</p><p>&#x02022;Epilepsy (recurrent seizures beyond the neonatal, period requiring anticonvulsant treatment)</p><p>&#x02022;Developmental delay</p><p>&#x02022;Multiple Disabilities (epilepsy, cortical visual impairment, sensorineural hearing loss, developmental delay)</p><p>Finally, the neuroradiologic outcome will be assessed by comparing the imaging obtained by standard cerebral MRI, DTI and spectroscopy performed within the first 7 days, at 3 months and 18 months of age. Brain injuries will be classified as isolated lesions of the white matter (WM), of basal ganglia and thalami (BGT), with or without involvement of the posterior limb of the internal capsule (PLIC), of cortex (COR), or various combinations of such lesions
[<xref ref-type="bibr" rid="B65">65</xref>].</p></sec><sec><title>Ethical approval</title><p>A three-centre phase II pilot study entitled &#x0201c;Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia (NeoNATI)&#x0201d; has been approved by the Ethics Committees of A. Meyer University Children&#x02019;s Hospital, Florence, of University of Pisa and of La Sapienza University, Rome (prot. 276/2010).</p><p>Informed consent will be obtained from at least one parent prior to study entry. Parents will be given full verbal and written information regarding the objective and procedures of the study and the possible risks involved.</p><p>TPM is considered safe for use in children. Nevertheless, a careful watch will be kept on all study participants with regard to side effects of drug administration. Parents of participants will be made aware of possible side effects. Infants will be monitored in the Neonatal Intensive Care Unit throughout the study period and their clinical condition will be evaluated daily as part of medical rounds. A letter informing the participant and the family doctor as to which study arm the participant had been randomized to will be sent following completion of the study.</p><p>In the presence of adverse events, a reduction of dosage will be taken into account.</p><p>For ethical and scientific reasons, an interim analysis after the enrolment of half of the newborns, is planned.</p></sec><sec><title>Exit criteria</title><p>Patients will be withdrawn from the study if parents make specific request for the treatment to be discontinued before 72 hours, in case of severe bleeding, thrombosis, or pulmonary hypertension difficult to treat, arrhythmia, clinical electroencephalographic or neuroimaging evidence of irreversible severe brain damage.</p></sec><sec><title>Measurement of outcomes</title><sec><title>Primary endpoint</title><p>To evaluate if the TPM administration reduces the cerebral damage of newborns with HIE and treated with therapeutic hypothermia, neurological and neuroradiologic follow-up are planned at different stages.</p></sec><sec><title>Secondary endpoint</title><p>a. To evaluate the safety of TPM treatment, cardiac and respiratory parameters (heart frequency, blood pressure, oxygen saturation, respiratory support) will be continuously monitored; blood samplings will be performed to check renal, liver and metabolic balance</p><p>b. To evaluate if TPM improves the functional and structural outcome, visual function is planned at 40 weeks gestational age, 4 &#x000bd;, 12, 18 and 24 months corrected age.</p></sec><sec><title>Confidentiality</title><p>The participants&#x02019; data collected during this trial will be kept confidential. Study staff will have access to the data as well as the participants&#x02019; medical records as they pertain to this study. Published results will not contain any information that would identify individual participants.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The objective of this research is highly ambitious: to find a treatment procedure that is simple, inexpensive, well tolerated and with few adverse effects, able to reduce post-ischemic neuronal damage. Neuroprotection is a major health care priority, given the enormous burden of human suffering and financial cost caused by perinatal brain damage. Hypothermic treatment is recognized as a neuroprotective treatment after a profound neonatal insult. However, it is clear from previously published clinical trials and animal studies that hypothermia alone does not provide complete protection. Neuroprotective drugs added during or after hypothermia might improve neurologic protection, by extending the therapeutic window or providing long-lasting additive or synergistic action
[<xref ref-type="bibr" rid="B133">133</xref>]. This combination treatment could open new perspectives for the management of asphyxiated infants. To date, no clinical study has evaluated the efficacy of the combined treatment hypothermia and TPM, an antiglutaminergic drug mainly used for the treatment of epilepsy. On the other hand, it is important to consider that drugs administered during the neonatal period may be dangerous to the immature brain, and hypothermia can modify their pharmacokinetics. In fact, excretion of many drugs and their metabolites can be modified by hypothermia; failure of liver and kidney clearance due to hypoxic-ischemic injury could exacerbate any toxicity. In newborns with HIE, TPM pharmacokinetic properties appear to be modified by concomitant hypothermia, but the dosage of 5 mg/kg appears safe. In this study the dosage will be increased to 10 mg/kg, likewise in other studies. For this reason one of the main objectives of this study is to confirm the safety of TPM added to hypothermia.</p></sec><sec><title>Abbreviations</title><p>HIE: Hypoxic ischemic encephalopathy; EEG: Electroencephalography; AMPA: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; NMDA: <italic>N</italic>-methyl-D-aspartate; TPM: Topiramate; MRI: Magnetic Resonance Imaging; DTI: Diffusion tensor imaging.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>LF conceived the study, he is Chief Investigator, participated in the design and helped to draft the manuscript. MD, SC, helped to draft the manuscript. MD, SC, LB, AB, MG, RS, PP, participated in the study design and are responsible for data collection. TP, MF, AS, FDB participated in the study design and are responsible for the neurological follow-up. SS, CF participated in the study design and are responsible for the radiological follow-up. FT participated in the study design and is responsible for the visual function evaluations. GLM, SM, MDB participated in the design of the study and are responsible for the determination of TPM concentration on dried blood spots. PF, GC, GD, RG participated in the design of the study and reviewed the protocol. All authors contributed to the development of the protocol, and read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2431/12/144/prepub">http://www.biomedcentral.com/1471-2431/12/144/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The authors would like to acknowledge the nurse staff of all the NICUs for their support.</p><p>They also would like to acknowledge the financial support from the Meyer Foundation - &#x0201c;A. Meyer&#x0201d; University Children&#x02019;s Hospital.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Finer</surname><given-names>NN</given-names></name><name><surname>Robertson</surname><given-names>CM</given-names></name><name><surname>Richards</surname><given-names>RT</given-names></name><name><surname>Pinnell</surname><given-names>LE</given-names></name><name><surname>Peters</surname><given-names>KL</given-names></name><article-title>Hypoxic-ischemic encephalopathy in term neonates: perinatal factors and outcome</article-title><source>J Pediatr</source><year>1981</year><volume>98</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(81)80555-0</pub-id><pub-id pub-id-type="pmid">7452386</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Thornberg</surname><given-names>E</given-names></name><name><surname>Thiringer</surname><given-names>K</given-names></name><name><surname>Odeback</surname><given-names>A</given-names></name><name><surname>Milsom</surname><given-names>I</given-names></name><article-title>Birth asphyxia: incidence, clinical course and outcome in a Swedish population</article-title><source>Acta Paediatr</source><year>1995</year><volume>84</volume><fpage>927</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.1995.tb13794.x</pub-id><pub-id pub-id-type="pmid">7488819</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Robertson</surname><given-names>CM</given-names></name><name><surname>Finer</surname><given-names>NN</given-names></name><name><surname>Grace</surname><given-names>MG</given-names></name><article-title>School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term</article-title><source>J Pediatr</source><year>1989</year><volume>114</volume><fpage>753</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(89)80132-5</pub-id><pub-id pub-id-type="pmid">2469789</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Shankaran</surname><given-names>S</given-names></name><name><surname>Woldt</surname><given-names>E</given-names></name><name><surname>Koepke</surname><given-names>T</given-names></name><name><surname>Bedard</surname><given-names>MP</given-names></name><name><surname>Nandyal</surname><given-names>R</given-names></name><article-title>Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants</article-title><source>Early Hum Dev</source><year>1991</year><volume>25</volume><fpage>136</fpage><lpage>148</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Busto</surname><given-names>R</given-names></name><name><surname>Globus</surname><given-names>MY</given-names></name><name><surname>Dietrich</surname><given-names>WD</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Valdes</surname><given-names>I</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name><article-title>Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain</article-title><source>Stroke</source><year>1989</year><volume>20</volume><fpage>904</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1161/01.STR.20.7.904</pub-id><pub-id pub-id-type="pmid">2568705</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Rosenberg</surname><given-names>PA</given-names></name><article-title>Excitatory amino acids as a final common pathway for neurologic disorders</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1056/NEJM199403033300907</pub-id><pub-id pub-id-type="pmid">7905600</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Olney</surname><given-names>JW</given-names></name><name><surname>Ho</surname><given-names>OL</given-names></name><article-title>Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine</article-title><source>Nature</source><year>1970</year><volume>227</volume><fpage>609</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">5464249</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Mayer</surname><given-names>ML</given-names></name><name><surname>Westbrook</surname><given-names>GL</given-names></name><name><surname>Guthrie</surname><given-names>PB</given-names></name><article-title>Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones</article-title><source>Nature</source><year>1984</year><volume>309</volume><fpage>261</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/309261a0</pub-id><pub-id pub-id-type="pmid">6325946</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Nowak</surname><given-names>L</given-names></name><name><surname>Bregestovski</surname><given-names>P</given-names></name><name><surname>Ascher</surname><given-names>P</given-names></name><name><surname>Herbet</surname><given-names>A</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name><article-title>Magnesium gates glutamate-activated channels in mouse central neurones</article-title><source>Nature</source><year>1984</year><volume>307</volume><fpage>462</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/307462a0</pub-id><pub-id pub-id-type="pmid">6320006</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Dingledine</surname><given-names>R</given-names></name><name><surname>Borges</surname><given-names>K</given-names></name><name><surname>Bowie</surname><given-names>D</given-names></name><name><surname>Traynelis</surname><given-names>SF</given-names></name><article-title>The glutamate receptor ion channels</article-title><source>Pharmacol Rev</source><year>1999</year><volume>51</volume><fpage>7</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10049997</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Nicotera</surname><given-names>P</given-names></name><article-title>Calcium, free radicals and excitotoxins in neuronal apoptosis</article-title><source>Cell Calcium</source><year>1998</year><volume>23</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0143-4160(98)90115-4</pub-id><pub-id pub-id-type="pmid">9601612</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>SA</given-names></name><article-title>Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond</article-title><source>Nat Rev Drug Discov</source><year>2006</year><volume>5</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nrd1958</pub-id><pub-id pub-id-type="pmid">16424917</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Armstead</surname><given-names>WM</given-names></name><name><surname>Mirro</surname><given-names>R</given-names></name><name><surname>Busija</surname><given-names>DW</given-names></name><name><surname>Leffler</surname><given-names>CW</given-names></name><article-title>Postischemic generation of superoxide anion by newborn pig brain</article-title><source>Am J Physiol</source><year>1988</year><volume>255</volume><fpage>H401</fpage><lpage>H403</lpage><pub-id pub-id-type="pmid">2841877</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Yue</surname><given-names>X</given-names></name><name><surname>Cox</surname><given-names>P</given-names></name><name><surname>Hope</surname><given-names>PL</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><name><surname>Squier</surname><given-names>MV</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><article-title>Apoptosis in the brains of infants suffering intrauterine cerebral injury</article-title><source>Pediatr Res</source><year>1997</year><volume>42</volume><fpage>684</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1203/00006450-199711000-00022</pub-id><pub-id pub-id-type="pmid">9357944</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Satas</surname><given-names>S</given-names></name><name><surname>Puka-Sundvall</surname><given-names>M</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Hallstrom</surname><given-names>A</given-names></name><name><surname>Loberg</surname><given-names>EM</given-names></name><name><surname>Ungerstedt</surname><given-names>U</given-names></name><name><surname>Steen</surname><given-names>PA</given-names></name><name><surname>Hagberg</surname><given-names>H</given-names></name><article-title>Post-hypoxic hypothermia reduces cerebrocortical release of NO and excitotoxins</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>3359</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1097/00001756-199710200-00033</pub-id><pub-id pub-id-type="pmid">9351672</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Amess</surname><given-names>PN</given-names></name><name><surname>Penrice</surname><given-names>J</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Lorek</surname><given-names>A</given-names></name><name><surname>Wylezinska</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>CE</given-names></name><name><surname>D'Souza</surname><given-names>P</given-names></name><name><surname>Tyszczuk</surname><given-names>L</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Wyatt</surname><given-names>JS</given-names></name><name><surname>Reynolds</surname><given-names>EO</given-names></name><article-title>Mild hypothermia after severe transient hypoxia-ischemia reduces the delayed rise in cerebral lactate in the newborn piglet</article-title><source>Pediatr Res</source><year>1997</year><volume>41</volume><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1203/00006450-199706000-00002</pub-id><pub-id pub-id-type="pmid">9167192</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Yue</surname><given-names>X</given-names></name><name><surname>Squier</surname><given-names>MV</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Penrice</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>CE</given-names></name><name><surname>Wyatt</surname><given-names>JS</given-names></name><name><surname>Reynolds</surname><given-names>EO</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><article-title>Specific inhibition of apoptosis after cerebral hypoxia-ischaemia by moderate post-insult hypothermia</article-title><source>Biochem Biophys Res Commun</source><year>1995</year><volume>217</volume><fpage>1193</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1995.2895</pub-id><pub-id pub-id-type="pmid">8554576</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Bonfoco</surname><given-names>E</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name><name><surname>Ankarcrona</surname><given-names>M</given-names></name><name><surname>Nicotera</surname><given-names>P</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><article-title>Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>7162</fpage><lpage>7166</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.16.7162</pub-id><pub-id pub-id-type="pmid">7638161</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>London</surname><given-names>ED</given-names></name><name><surname>Bredt</surname><given-names>DS</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name><article-title>Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>6368</fpage><lpage>6371</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.14.6368</pub-id><pub-id pub-id-type="pmid">1648740</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>SA</given-names></name><article-title>Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide</article-title><source>Trends Neurosci</source><year>1993</year><volume>16</volume><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(93)90198-U</pub-id><pub-id pub-id-type="pmid">7509524</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Budd</surname><given-names>SL</given-names></name><name><surname>Tenneti</surname><given-names>L</given-names></name><name><surname>Lishnak</surname><given-names>T</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><article-title>Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>6161</fpage><lpage>6166</lpage><pub-id pub-id-type="doi">10.1073/pnas.100121097</pub-id><pub-id pub-id-type="pmid">10811898</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Hara</surname><given-names>MR</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>SF</given-names></name><name><surname>Cascio</surname><given-names>MB</given-names></name><name><surname>Fujimuro</surname><given-names>M</given-names></name><name><surname>Ozeki</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>JH</given-names></name><name><surname>Tankou</surname><given-names>SK</given-names></name><name><surname>Hester</surname><given-names>LD</given-names></name><name><surname>Ferris</surname><given-names>CD</given-names></name><name><surname>Hayward</surname><given-names>SD</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name><name><surname>Sawa</surname><given-names>A</given-names></name><article-title>S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1038/ncb1268</pub-id><pub-id pub-id-type="pmid">15951807</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Busto</surname><given-names>R</given-names></name><name><surname>Dietrich</surname><given-names>WD</given-names></name><name><surname>Globus</surname><given-names>MY</given-names></name><name><surname>Valdes</surname><given-names>I</given-names></name><name><surname>Scheinberg</surname><given-names>P</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name><article-title>Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury</article-title><source>J Cerebr Blood Flow Metab</source><year>1987</year><volume>7</volume><fpage>729</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1987.127</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Dietrich</surname><given-names>WD</given-names></name><article-title>The importance of brain temperature in cerebral injury</article-title><source>J Neurotrauma</source><year>1992</year><volume>9</volume><issue>Suppl 2</issue><fpage>S475</fpage><lpage>S485</lpage><pub-id pub-id-type="pmid">1613807</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Wyatt</surname><given-names>J</given-names></name><article-title>Keeping a cool head, post-hypoxic hypothermia - an old idea revisited</article-title><source>Acta Paediatr</source><year>1997</year><volume>86</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.1997.tb14799.x</pub-id><pub-id pub-id-type="pmid">9350876</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><article-title>Cooling the newborn after asphyxia - physiological and experimental background and its clinical use</article-title><source>Semin Neonatol</source><year>2000</year><volume>5</volume><fpage>61</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1053/siny.1999.0118</pub-id><pub-id pub-id-type="pmid">10802751</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Colbourne</surname><given-names>F</given-names></name><name><surname>Corbett</surname><given-names>D</given-names></name><article-title>Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection</article-title><source>J Neurosci</source><year>1995</year><volume>15</volume><fpage>7250</fpage><lpage>7260</lpage><pub-id pub-id-type="pmid">7472479</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Bona</surname><given-names>E</given-names></name><name><surname>Hagberg</surname><given-names>H</given-names></name><name><surname>Loberg</surname><given-names>EM</given-names></name><name><surname>Bagenholm</surname><given-names>R</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><article-title>Protective effects of moderate hypothermia after neonatal hypoxia-ischemia: short- and long-term outcome</article-title><source>Pediatr Res</source><year>1998</year><volume>43</volume><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1203/00006450-199806000-00005</pub-id><pub-id pub-id-type="pmid">9621982</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>BP</given-names></name><name><surname>Nedelcu</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><article-title>Delayed postischemic hypothermia improves long-term behavioral outcome after cerebral hypoxia-ischemia in neonatal rats</article-title><source>Pediatr Res</source><year>2002</year><volume>51</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1203/00006450-200203000-00015</pub-id><pub-id pub-id-type="pmid">11861942</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Asai</surname><given-names>S</given-names></name><name><surname>Kanematsu</surname><given-names>K</given-names></name><name><surname>Kunimatsu</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><article-title>Real-time monitoring of the effects of normothermia and hypothermia on extracellular glutamate re-uptake in the rat following global brain ischemia</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>2389</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1097/00001756-199707070-00057</pub-id><pub-id pub-id-type="pmid">9243646</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Penrice</surname><given-names>J</given-names></name><name><surname>Lorek</surname><given-names>A</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Wylezinska</surname><given-names>M</given-names></name><name><surname>Kirkbride</surname><given-names>V</given-names></name><name><surname>Cooper</surname><given-names>CE</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Wyatt</surname><given-names>JS</given-names></name><article-title>Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet</article-title><source>Pediatr Res</source><year>1995</year><volume>37</volume><fpage>667</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1203/00006450-199505000-00019</pub-id><pub-id pub-id-type="pmid">7603788</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Globus</surname><given-names>MY</given-names></name><name><surname>Busto</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Schnippering</surname><given-names>H</given-names></name><name><surname>Ginsberg</surname><given-names>MD</given-names></name><article-title>Detection of free radical activity during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation</article-title><source>J Neurochem</source><year>1995</year><volume>65</volume><fpage>1250</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">7643104</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>AT</given-names></name><article-title>Effect of hypothermia on microglial reaction in ischemic brain</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>947</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1097/00001756-199703030-00026</pub-id><pub-id pub-id-type="pmid">9141070</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Si</surname><given-names>QS</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><article-title>Hypothermic suppression of microglial activation in culture: inhibition of cell proliferation and production of nitric oxide and superoxide</article-title><source>Neuroscience</source><year>1997</year><volume>81</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(97)00172-3</pub-id><pub-id pub-id-type="pmid">9300414</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Weinrauch</surname><given-names>V</given-names></name><name><surname>Safar</surname><given-names>P</given-names></name><name><surname>Tisherman</surname><given-names>S</given-names></name><name><surname>Kuboyama</surname><given-names>K</given-names></name><name><surname>Radovsky</surname><given-names>A</given-names></name><article-title>Beneficial effect of mild hypothermia and detrimental effect of deep hypothermia after cardiac arrest in dogs</article-title><source>Stroke</source><year>1992</year><volume>23</volume><fpage>1454</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1161/01.STR.23.10.1454</pub-id><pub-id pub-id-type="pmid">1412583</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Chopp</surname><given-names>M</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Tidwell</surname><given-names>CD</given-names></name><name><surname>Helpern</surname><given-names>JA</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Welch</surname><given-names>KM</given-names></name><article-title>The metabolic effects of mild hypothermia on global cerebral ischemia and recirculation in the cat: comparison to normothermia and hyperthermia</article-title><source>J Cereb Blood Flow Metab</source><year>1989</year><volume>9</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1989.21</pub-id><pub-id pub-id-type="pmid">2921288</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Clifton</surname><given-names>GL</given-names></name><name><surname>Jiang</surname><given-names>JY</given-names></name><name><surname>Lyeth</surname><given-names>BG</given-names></name><name><surname>Jenkins</surname><given-names>LW</given-names></name><name><surname>Hamm</surname><given-names>RJ</given-names></name><name><surname>Hayes</surname><given-names>RL</given-names></name><article-title>Marked protection by moderate hypothermia after experimental traumatic brain injury</article-title><source>J Cereb Blood Flow Metab</source><year>1991</year><volume>11</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1991.13</pub-id><pub-id pub-id-type="pmid">1983995</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Coimbra</surname><given-names>C</given-names></name><name><surname>Wieloch</surname><given-names>T</given-names></name><article-title>Moderate hypothermia mitigates neuronal damage in the rat brain when initiated several hours following transient cerebral ischemia</article-title><source>Acta Neuropathol</source><year>1994</year><volume>87</volume><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1007/BF00313599</pub-id><pub-id pub-id-type="pmid">8017166</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>DL</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><article-title>Improved neuroprotection with hypothermia delayed by 6 hours following cerebral hypoxia-ischemia in the 14-day-old rat</article-title><source>Pediatr Res</source><year>2002</year><volume>51</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1203/00006450-200201000-00005</pub-id><pub-id pub-id-type="pmid">11756634</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Colbourne</surname><given-names>F</given-names></name><name><surname>Corbett</surname><given-names>D</given-names></name><article-title>Delayed and prolonged post-ischemic hypothermia in neuroprotective in the gerbil</article-title><source>Brain Res</source><year>1994</year><volume>654</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)90488-X</pub-id><pub-id pub-id-type="pmid">7987676</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Gunn</surname><given-names>AJ</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name><name><surname>Gunning</surname><given-names>MI</given-names></name><name><surname>Williams</surname><given-names>CE</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><article-title>Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep</article-title><source>Pediatrics</source><year>1998</year><volume>102</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1542/peds.102.5.1098</pub-id><pub-id pub-id-type="pmid">9794940</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Sirimanne</surname><given-names>ES</given-names></name><name><surname>Blumberg</surname><given-names>RM</given-names></name><name><surname>Bossano</surname><given-names>D</given-names></name><name><surname>Gunning</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Williams</surname><given-names>CE</given-names></name><article-title>The effect of prolonged modification of cerebral temperature on outcome after hypoxic-ischemic brain injury in the infant rat</article-title><source>Pediatr Res</source><year>1996</year><volume>39</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1203/00006450-199604000-00005</pub-id><pub-id pub-id-type="pmid">8848330</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Gunn</surname><given-names>AJ</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name><name><surname>de Haan</surname><given-names>HH</given-names></name><name><surname>Williams</surname><given-names>CE</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><article-title>Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs</article-title><source>J Clin Invest</source><year>1997</year><volume>99</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1172/JCI119153</pub-id><pub-id pub-id-type="pmid">9005993</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Chopp</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Dereski</surname><given-names>MO</given-names></name><name><surname>Garcia</surname><given-names>JH</given-names></name><article-title>Mild hypothermic intervention after graded ischemic stress in rats</article-title><source>Stroke</source><year>1991</year><volume>22</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1161/01.STR.22.1.37</pub-id><pub-id pub-id-type="pmid">1987671</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Bagenholm</surname><given-names>R</given-names></name><name><surname>Loberg</surname><given-names>EM</given-names></name><name><surname>Apricena</surname><given-names>F</given-names></name><name><surname>Kjellmer</surname><given-names>I</given-names></name><article-title>Posthypoxic cooling of neonatal rats provides protection against brain injury</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>1996</year><volume>74</volume><fpage>F3</fpage><lpage>F9</lpage><pub-id pub-id-type="doi">10.1136/fn.74.1.F3</pub-id><pub-id pub-id-type="pmid">8653432</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Bona</surname><given-names>E</given-names></name><name><surname>Loberg</surname><given-names>E</given-names></name><name><surname>Bagenholm</surname><given-names>R</given-names></name><name><surname>Hagberg</surname><given-names>H</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><article-title>Protective effects of moderate hypothermia after neonatal hypoxia-ischemia: short- and long-term outcome</article-title><source>Pediatr Res</source><year>1998</year><volume>43</volume><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1203/00006450-199806000-00005</pub-id><pub-id pub-id-type="pmid">9621982</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Colbourne</surname><given-names>F</given-names></name><name><surname>Auer</surname><given-names>RN</given-names></name><name><surname>Sutherland</surname><given-names>GR</given-names></name><article-title>Characterization of postischemic behavioral deficits in gerbils with and without hypothermic neuroprotection</article-title><source>Brain Res</source><year>1998</year><volume>803</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(98)00612-X</pub-id><pub-id pub-id-type="pmid">9729285</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Corbett</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>M</given-names></name><name><surname>Colbourne</surname><given-names>F</given-names></name><article-title>Persistent neuroprotection with prolonged postischemic hypothermia in adult rats subjected to transient middle cerebral artery occlusion</article-title><source>Exp Neurol</source><year>2000</year><volume>163</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1006/exnr.2000.7369</pub-id><pub-id pub-id-type="pmid">10785459</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Colbourne</surname><given-names>F</given-names></name><name><surname>Corbett</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Buchan</surname><given-names>AM</given-names></name><article-title>Prolonged but delayed postischemic hypothermia: a long-term outcome study in the rat middle cerebral artery occlusion model</article-title><source>J Cereb Blood Flow Metab</source><year>2000</year><volume>20</volume><fpage>1702</fpage><lpage>1708</lpage><pub-id pub-id-type="pmid">11129786</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Westin</surname><given-names>B</given-names></name><name><surname>Nyberg</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Wedenberg</surname><given-names>E</given-names></name><article-title>Hypothermia and transfusion with oxygenated blood in the treatment of asphyxia neonatorum</article-title><source>Acta Paediatr Scand</source><year>1962</year><volume>51</volume><issue>suppl 139</issue><fpage>1</fpage><lpage>80</lpage></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Cordey</surname><given-names>R</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JA</given-names><suffix>Jr</suffix></name><article-title>Resuscitation of neonates by hypothermia: report on 20 cases with acid&#x02013;base determination on 10 cases and the long-term development of 33 cases</article-title><source>Resuscitation</source><year>1973</year><volume>2</volume><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/0300-9572(73)90042-7</pub-id><pub-id pub-id-type="pmid">4773063</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Westin</surname><given-names>B</given-names></name><article-title>Infant resuscitation and prevention of mental retardation</article-title><source>Am J Obstet Gynecol</source><year>1971</year><volume>110</volume><fpage>1134</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">4935088</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Dunn</surname><given-names>JM</given-names></name><name><surname>Miller</surname><given-names>JA</given-names><suffix>Jr</suffix></name><article-title>Hypothermia combined with positive pressure ventilation in resuscitation of the asphyxiated neonate. Clinical observations in 28 infants</article-title><source>Am J Obstet Gynecol</source><year>1969</year><volume>104</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">4888017</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Ehrstrom</surname><given-names>J</given-names></name><name><surname>Hirvensalo</surname><given-names>M</given-names></name><name><surname>Donner</surname><given-names>M</given-names></name><name><surname>Hietalahti</surname><given-names>J</given-names></name><article-title>Hypothermia in the resuscitation of severely asphyctic newborn infants. A follow-up study</article-title><source>Ann Clin Res</source><year>1969</year><volume>1</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">5350770</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>FS</given-names></name><name><surname>Westin</surname><given-names>B</given-names></name><article-title>Hypothermia in the treatment of asphyxia neonatorum</article-title><source>Biol Neonate</source><year>1964</year><volume>6</volume><fpage>148</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1159/000239893</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Gunn</surname><given-names>AJ</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name><article-title>Selective head cooling in newborn infants after perinatal asphyxia: a safety study</article-title><source>Pediatrics</source><year>1998</year><volume>102</volume><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1542/peds.102.4.885</pub-id><pub-id pub-id-type="pmid">9755260</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Simbruner</surname><given-names>G</given-names></name><name><surname>Haberl</surname><given-names>C</given-names></name><name><surname>Harrison</surname><given-names>V</given-names></name><name><surname>Linley</surname><given-names>L</given-names></name><name><surname>Willeitner</surname><given-names>AE</given-names></name><article-title>Induced brain hypothermia in asphyxiated human newborn infants: a retrospective chart analysis of physiological and adverse effects</article-title><source>Intensive Care Med</source><year>1999</year><volume>25</volume><fpage>1111</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1007/s001340051020</pub-id><pub-id pub-id-type="pmid">10551967</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><article-title>Cardiovascular changes during mild therapeutic hypothermia and rewarming in infants with hypoxic-ischemic encephalopathy</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1542/peds.106.1.92</pub-id><pub-id pub-id-type="pmid">10878155</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Azzopardi</surname><given-names>D</given-names></name><name><surname>Robertson</surname><given-names>NJ</given-names></name><name><surname>Cowan</surname><given-names>FM</given-names></name><name><surname>Rutherford</surname><given-names>MA</given-names></name><name><surname>Rampling</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><article-title>Pilot study of treatment with whole body hypothermia for neonatal encephalopathy</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>684</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1542/peds.106.4.684</pub-id><pub-id pub-id-type="pmid">11015509</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Shankaran</surname><given-names>S</given-names></name><name><surname>Laptook</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Donovan</surname><given-names>EF</given-names></name><name><surname>Fanaroff</surname><given-names>AA</given-names></name><name><surname>Stark</surname><given-names>AR</given-names></name><name><surname>Tyson</surname><given-names>JE</given-names></name><name><surname>Poole</surname><given-names>K</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><name><surname>Lemons</surname><given-names>JA</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Papile</surname><given-names>LA</given-names></name><name><surname>Bauer</surname><given-names>CR</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Korones</surname><given-names>SB</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><article-title>Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants</article-title><source>Pediatrics</source><year>2002</year><volume>110</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1542/peds.110.2.377</pub-id><pub-id pub-id-type="pmid">12165594</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Battin</surname><given-names>MR</given-names></name><name><surname>Penrice</surname><given-names>J</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name><name><surname>Gunn</surname><given-names>AJ</given-names></name><article-title>Treatment of term infants with head cooling and mild systemic hypothermia (35.0 degrees C and 34.5 degrees C) after perinatal asphyxia</article-title><source>Pediatrics</source><year>2003</year><volume>111</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1542/peds.111.2.244</pub-id><pub-id pub-id-type="pmid">12563046</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Debillon</surname><given-names>T</given-names></name><name><surname>Daoud</surname><given-names>P</given-names></name><name><surname>Durand</surname><given-names>P</given-names></name><name><surname>Cantagrel</surname><given-names>S</given-names></name><name><surname>Jouvet</surname><given-names>P</given-names></name><name><surname>Saizou</surname><given-names>C</given-names></name><name><surname>Zupan</surname><given-names>V</given-names></name><article-title>Whole-body cooling after perinatal asphyxia: a pilot study in term neonates</article-title><source>Dev Med Child Neurol</source><year>2003</year><volume>45</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12553298</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Battin</surname><given-names>MR</given-names></name><name><surname>Dezoete</surname><given-names>JA</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Gunn</surname><given-names>AJ</given-names></name><article-title>Neurodevelopmental outcome of infants treated with head cooling and mild hypothermia after perinatal asphyxia</article-title><source>Pediatrics</source><year>2001</year><volume>107</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1542/peds.107.3.480</pub-id><pub-id pub-id-type="pmid">11230586</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Inder</surname><given-names>TE</given-names></name><name><surname>Hunt</surname><given-names>RW</given-names></name><name><surname>Morley</surname><given-names>CJ</given-names></name><name><surname>Coleman</surname><given-names>L</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><name><surname>Jacobs</surname><given-names>SE</given-names></name><article-title>Randomized trial of systemic hypothermia selectively protects the cortex on MRI in term hypoxic-ischemic encephalopathy</article-title><source>J Pediatr</source><year>2004</year><volume>145</volume><fpage>835</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.07.034</pub-id><pub-id pub-id-type="pmid">15580212</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Rutherford</surname><given-names>MA</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Cowan</surname><given-names>F</given-names></name><name><surname>Renowden</surname><given-names>S</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><article-title>Mild hypothermia and the distribution of cerebral lesions in neonates with hypoxic-ischemic encephalopathy</article-title><source>Pediatrics</source><year>2005</year><volume>116</volume><fpage>1001</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1542/peds.2005-0328</pub-id><pub-id pub-id-type="pmid">16199715</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Wyatt</surname><given-names>JS</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Ferriero</surname><given-names>DM</given-names></name><name><surname>Polin</surname><given-names>RA</given-names></name><name><surname>Robertson</surname><given-names>CM</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Gunn</surname><given-names>AJ</given-names></name><article-title>Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">15721471</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Eicher</surname><given-names>DJ</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name><name><surname>Katikaneni</surname><given-names>LP</given-names></name><name><surname>Hulsey</surname><given-names>TC</given-names></name><name><surname>Bass</surname><given-names>WT</given-names></name><name><surname>Kaufman</surname><given-names>DA</given-names></name><name><surname>Horgan</surname><given-names>MJ</given-names></name><name><surname>Languani</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>JJ</given-names></name><name><surname>Givelichian</surname><given-names>LM</given-names></name><name><surname>Sankaran</surname><given-names>K</given-names></name><name><surname>Yager</surname><given-names>JY</given-names></name><article-title>Moderate hypothermia in neonatal encephalopathy: efficacy outcomes</article-title><source>Pediatr Neurol</source><year>2005</year><volume>32</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2004.06.014</pub-id><pub-id pub-id-type="pmid">15607598</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Shankaran</surname><given-names>S</given-names></name><name><surname>Laptook</surname><given-names>AR</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Tyson</surname><given-names>JE</given-names></name><name><surname>McDonald</surname><given-names>SA</given-names></name><name><surname>Donovan</surname><given-names>EF</given-names></name><name><surname>Fanaroff</surname><given-names>AA</given-names></name><name><surname>Poole</surname><given-names>WK</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Higgins</surname><given-names>RD</given-names></name><name><surname>Finer</surname><given-names>NN</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><name><surname>Duara</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Cotten</surname><given-names>CM</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Lemons</surname><given-names>JA</given-names></name><name><surname>Guillet</surname><given-names>R</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><collab>National Institute of Child Health and Human Development Neonatal Research Network</collab><article-title>Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1574</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1056/NEJMcps050929</pub-id><pub-id pub-id-type="pmid">16221780</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Azzopardi</surname><given-names>DV</given-names></name><name><surname>Strohm</surname><given-names>B</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Dyet</surname><given-names>L</given-names></name><name><surname>Halliday</surname><given-names>HL</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Kapellou</surname><given-names>O</given-names></name><name><surname>Levene</surname><given-names>M</given-names></name><name><surname>Marlow</surname><given-names>N</given-names></name><name><surname>Porter</surname><given-names>E</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Brocklehurst</surname><given-names>P</given-names></name><collab>TOBY Study Group</collab><article-title>Moderate hypothermia to treat perinatal asphyxial encephalopathy</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1349</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0900854</pub-id><pub-id pub-id-type="pmid">19797281</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Jacobs</surname><given-names>SE</given-names></name><name><surname>Morley</surname><given-names>CJ</given-names></name><name><surname>Inder</surname><given-names>TE</given-names></name><name><surname>Stewart</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>KR</given-names></name><name><surname>McNamara</surname><given-names>PJ</given-names></name><name><surname>Wright</surname><given-names>IM</given-names></name><name><surname>Kirpalani</surname><given-names>HM</given-names></name><name><surname>Darlow</surname><given-names>BA</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><article-title>Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial</article-title><source>Arch Pediatr Adolesc Med</source><year>2011</year><volume>165</volume><issue>8</issue><fpage>692</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1001/archpediatrics.2011.43</pub-id><pub-id pub-id-type="pmid">21464374</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Simbruner</surname><given-names>G</given-names></name><name><surname>Mittal</surname><given-names>RA</given-names></name><name><surname>Rohlmann</surname><given-names>F</given-names></name><name><surname>Muche</surname><given-names>R</given-names></name><article-title>neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><issue>4</issue><fpage>e771</fpage><lpage>e778</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-2441</pub-id><pub-id pub-id-type="pmid">20855387</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>WH</given-names></name><name><surname>Cheng</surname><given-names>GQ</given-names></name><name><surname>Shao</surname><given-names>XM</given-names></name><name><surname>Liu</surname><given-names>XZ</given-names></name><name><surname>Shan</surname><given-names>RB</given-names></name><name><surname>Zhuang</surname><given-names>DY</given-names></name><name><surname>Zhou</surname><given-names>CL</given-names></name><name><surname>Du</surname><given-names>LZ</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><article-title>China Study Group. Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy: a multicenter randomized controlled trial in China</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><issue>3</issue><fpage>367</fpage><lpage>372</lpage><comment>372.e1-3</comment><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.03.030</pub-id><pub-id pub-id-type="pmid">20488453</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Brocklehurst</surname><given-names>P</given-names></name><name><surname>Gunn</surname><given-names>AJ</given-names></name><name><surname>Halliday</surname><given-names>H</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Levene</surname><given-names>M</given-names></name><name><surname>Strohm</surname><given-names>B</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><article-title>Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data</article-title><source>BMJ</source><year>2010</year><volume>9</volume><fpage>340</fpage><lpage>c363</lpage></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Guillet</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Ferriero</surname><given-names>DM</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Whitelaw</surname><given-names>A</given-names></name><name><surname>Gunn</surname><given-names>AJ</given-names></name><article-title>Seven- to eight-year follow-up of the CoolCap trial of head cooling for neonatal encephalopathy</article-title><source>Pediatr Res</source><year>2012</year><volume>71</volume><issue>2</issue><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/pr.2011.30</pub-id><pub-id pub-id-type="pmid">22258133</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Shankaran</surname><given-names>S</given-names></name><article-title>Extended Hypothermia Follow-Up Sub Committee, Follow-Up PI&#x02019;s of the NICHD NRN. Do neuroprotective effects of whole body hypothermia for neonatal hypoxic-ischemic encephalopathy persist to childhood? [abstract]</article-title><source>Pediatr Acad Soc</source><year>2011</year><volume>1660</volume><fpage>8</fpage></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Eicher</surname><given-names>DJ</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name><name><surname>Katikaneni</surname><given-names>LP</given-names></name><name><surname>Hulsey</surname><given-names>TC</given-names></name><name><surname>Bass</surname><given-names>WT</given-names></name><name><surname>Kaufman</surname><given-names>DA</given-names></name><name><surname>Horgan</surname><given-names>MJ</given-names></name><name><surname>Languani</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>JJ</given-names></name><name><surname>Givelichian</surname><given-names>LM</given-names></name><name><surname>Sankaran</surname><given-names>K</given-names></name><name><surname>Yager</surname><given-names>JY</given-names></name><article-title>Moderate hypothermia in neonatal encephalopathy: safety outcomes</article-title><source>Pediatr Neurol</source><year>2005</year><volume>32</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2004.06.015</pub-id><pub-id pub-id-type="pmid">15607599</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Gebauer</surname><given-names>CM</given-names></name><name><surname>Knuepfer</surname><given-names>M</given-names></name><name><surname>Robel-Tillig</surname><given-names>E</given-names></name><name><surname>Pulzer</surname><given-names>F</given-names></name><name><surname>Vogtmann</surname><given-names>C</given-names></name><article-title>Hemodynamics among neonates with hypoxic-ischemic encephalopathy during whole-body hypothermia and passive rewarming</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1542/peds.2004-1587</pub-id><pub-id pub-id-type="pmid">16510666</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Perlman</surname><given-names>M</given-names></name><article-title>Hypothermia to treat neonatal hypoxic ischemic encephalopathy: systematic review</article-title><source>Arch Pediatr Adolesc Med</source><year>2007</year><volume>161</volume><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1001/archpedi.161.10.951</pub-id><pub-id pub-id-type="pmid">17909138</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>Shankaran</surname><given-names>S</given-names></name><name><surname>Pappas</surname><given-names>A</given-names></name><name><surname>Laptook</surname><given-names>AR</given-names></name><name><surname>McDonald</surname><given-names>SA</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Tyson</surname><given-names>JE</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Goldberg</surname><given-names>RN</given-names></name><name><surname>Higgins</surname><given-names>RD</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><article-title>NICHD Neonatal Research Network. Outcomes of safety and effectiveness in a multicenter randomized, controlled trial of whole-body hypothermia for neonatal hypoxic-ischemic encephalopathy</article-title><source>Pediatrics</source><year>2008</year><volume>122</volume><issue>4</issue><fpage>e791</fpage><lpage>e798</lpage><pub-id pub-id-type="doi">10.1542/peds.2008-0456</pub-id><pub-id pub-id-type="pmid">18829776</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Perlman</surname><given-names>JM</given-names></name><name><surname>Wyllie</surname><given-names>J</given-names></name><name><surname>Kattwinkel</surname><given-names>J</given-names></name><name><surname>Atkins</surname><given-names>DL</given-names></name><name><surname>Chameides</surname><given-names>L</given-names></name><name><surname>Goldsmith</surname><given-names>JP</given-names></name><name><surname>Guinsburg</surname><given-names>R</given-names></name><name><surname>Hazinski</surname><given-names>MF</given-names></name><name><surname>Morley</surname><given-names>C</given-names></name><name><surname>Richmond</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>WM</given-names></name><name><surname>Singhal</surname><given-names>N</given-names></name><name><surname>Szyld</surname><given-names>E</given-names></name><name><surname>Tamura</surname><given-names>M</given-names></name><name><surname>Velaphi</surname><given-names>S</given-names></name><article-title>Neonatal Resuscitation Chapter Collaborators. Neonatal resuscitation: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><issue>5</issue><fpage>e1319</fpage><lpage>e1344</lpage><pub-id pub-id-type="doi">10.1542/peds.2010-2972B</pub-id><pub-id pub-id-type="pmid">20956431</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Kattwinkel</surname><given-names>J</given-names></name><name><surname>Perlman</surname><given-names>JM</given-names></name><name><surname>Aziz</surname><given-names>K</given-names></name><name><surname>Colby</surname><given-names>C</given-names></name><name><surname>Fairchild</surname><given-names>K</given-names></name><name><surname>Gallagher</surname><given-names>J</given-names></name><name><surname>Hazinski</surname><given-names>MF</given-names></name><name><surname>Halamek</surname><given-names>LP</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Little</surname><given-names>G</given-names></name><name><surname>McGowan</surname><given-names>JE</given-names></name><name><surname>Nightengale</surname><given-names>B</given-names></name><name><surname>Ramirez</surname><given-names>MM</given-names></name><name><surname>Ringer</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>WM</given-names></name><name><surname>Weiner</surname><given-names>GM</given-names></name><name><surname>Wyckoff</surname><given-names>M</given-names></name><name><surname>Zaichkin</surname><given-names>J</given-names></name><article-title>American Heart Association. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><issue>5</issue><fpage>e1400</fpage><lpage>e1413</lpage><pub-id pub-id-type="doi">10.1542/peds.2010-2972E</pub-id><pub-id pub-id-type="pmid">20956432</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name><surname>Perlman</surname><given-names>JM</given-names></name><article-title>Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>S28</fpage><lpage>S33</lpage><pub-id pub-id-type="pmid">16777819</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Guerrini</surname><given-names>R</given-names></name><name><surname>Parmeggiani</surname><given-names>L</given-names></name><article-title>Topiramate and its clinical applications in epilepsy</article-title><source>Expert Opin Pharmacother</source><year>2006</year><volume>7</volume><fpage>811</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1517/14656566.7.6.811</pub-id><pub-id pub-id-type="pmid">16556095</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Shank</surname><given-names>RP</given-names></name><name><surname>Gardocki</surname><given-names>JF</given-names></name><name><surname>Streeter</surname><given-names>AJ</given-names></name><name><surname>Maryanoff</surname><given-names>BE</given-names></name><article-title>An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action</article-title><source>Epilepsia</source><year>2000</year><volume>41</volume><issue>suppl 1</issue><fpage>S3</fpage><lpage>S9</lpage><pub-id pub-id-type="pmid">10768292</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Martella</surname><given-names>G</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Prosperetti</surname><given-names>C</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Di Filippo</surname><given-names>M</given-names></name><name><surname>Pisani</surname><given-names>F</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><article-title>Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>1319</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000217303.22856.38</pub-id><pub-id pub-id-type="pmid">16574927</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Shuaib</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Siddiqui</surname><given-names>MM</given-names></name><article-title>Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization</article-title><source>Brain Res</source><year>1998</year><volume>804</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(98)00410-7</pub-id><pub-id pub-id-type="pmid">9757028</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SR</given-names></name><name><surname>Kim</surname><given-names>SP</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><article-title>Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils</article-title><source>Neurosci Lett</source><year>2000</year><volume>281</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(00)00847-8</pub-id><pub-id pub-id-type="pmid">10704773</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>Edmonds</surname><given-names>HL</given-names><suffix>Jr</suffix></name><name><surname>Jiang</surname><given-names>YD</given-names></name><name><surname>Zhang</surname><given-names>PY</given-names></name><name><surname>Shank</surname><given-names>R</given-names></name><article-title>Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration</article-title><source>Life Sci</source><year>2001</year><volume>69</volume><fpage>2265</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(01)01306-6</pub-id><pub-id pub-id-type="pmid">11669469</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Schubert</surname><given-names>S</given-names></name><name><surname>Brandl</surname><given-names>U</given-names></name><name><surname>Brodhun</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>C</given-names></name><name><surname>Spaltmann</surname><given-names>J</given-names></name><name><surname>Fiedler</surname><given-names>N</given-names></name><name><surname>Bauer</surname><given-names>R</given-names></name><article-title>Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets</article-title><source>Brain Res</source><year>2005</year><volume>1058</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2005.07.061</pub-id><pub-id pub-id-type="pmid">16139822</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Barks</surname><given-names>JD</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Silverstein</surname><given-names>FS</given-names></name><article-title>Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>1460</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000128029.50221.fa</pub-id><pub-id pub-id-type="pmid">15105511</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>Noh</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Choi</surname><given-names>HC</given-names></name><name><surname>Lim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>IH</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Eun</surname><given-names>BL</given-names></name><article-title>Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats</article-title><source>Exp Neurol</source><year>2006</year><volume>201</volume><fpage>470</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2006.04.038</pub-id><pub-id pub-id-type="pmid">16884714</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Follett</surname><given-names>PL</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Talos</surname><given-names>DM</given-names></name><name><surname>Massillon</surname><given-names>LJ</given-names></name><name><surname>Rosenberg</surname><given-names>PA</given-names></name><name><surname>Volpe</surname><given-names>JJ</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name><article-title>Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>4412</fpage><lpage>4420</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0477-04.2004</pub-id><pub-id pub-id-type="pmid">15128855</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>WK</given-names></name><article-title>Is topiramate a potential therapeutic agent for cerebral hypoxic/ischemic injury?</article-title><source>Exp Neurol</source><year>2007</year><volume>203</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2006.09.014</pub-id><pub-id pub-id-type="pmid">17070522</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Angehagen</surname><given-names>M</given-names></name><name><surname>R&#x000f6;nnb&#x000e4;ck</surname><given-names>L</given-names></name><name><surname>Hansson</surname><given-names>E</given-names></name><name><surname>Ben-Menachem</surname><given-names>E</given-names></name><article-title>Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures</article-title><source>J Neurochem</source><year>2005</year><volume>94</volume><fpage>1124</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03259.x</pub-id><pub-id pub-id-type="pmid">16092949</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Kaminski</surname><given-names>RM</given-names></name><name><surname>Banerjee</surname><given-names>M</given-names></name><name><surname>Rogawski</surname><given-names>MA</given-names></name><article-title>Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist</article-title><source>Neuropharmacology</source><year>2004</year><volume>46</volume><fpage>1097</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.02.010</pub-id><pub-id pub-id-type="pmid">15111016</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name><surname>Koh</surname><given-names>S</given-names></name><name><surname>Tibayan</surname><given-names>FD</given-names></name><name><surname>Simpson</surname><given-names>JN</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name><article-title>NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury</article-title><source>Epilepsia</source><year>2004</year><volume>45</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.69103.x</pub-id><pub-id pub-id-type="pmid">15144420</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name><surname>Sfaello</surname><given-names>I</given-names></name><name><surname>Baud</surname><given-names>O</given-names></name><name><surname>Arzimanoglou</surname><given-names>A</given-names></name><name><surname>Gressens</surname><given-names>P</given-names></name><article-title>Topiramate prevents excitotoxic damage in the newborn rodent brain</article-title><source>Neurobiol Dis</source><year>2005</year><volume>20</volume><fpage>837</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.05.019</pub-id><pub-id pub-id-type="pmid">16009561</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name><surname>Zona</surname><given-names>C</given-names></name><name><surname>Ciotti</surname><given-names>MT</given-names></name><name><surname>Avoli</surname><given-names>M</given-names></name><article-title>Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells</article-title><source>Neurosci Lett</source><year>1997</year><volume>231</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(97)00543-0</pub-id><pub-id pub-id-type="pmid">9300637</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name><surname>Dodgson</surname><given-names>SJ</given-names></name><name><surname>Shank</surname><given-names>RP</given-names></name><name><surname>Maryanoff</surname><given-names>BE</given-names></name><article-title>Topiramate as an inhibitor of carbonic anhydrase isoenzymes</article-title><source>Epilepsia</source><year>2000</year><volume>41</volume><issue>suppl 1</issue><fpage>S35</fpage><lpage>S39</lpage><pub-id pub-id-type="pmid">10768298</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name><surname>Kudin</surname><given-names>AP</given-names></name><name><surname>Debska-Vielhaber</surname><given-names>G</given-names></name><name><surname>Vielhaber</surname><given-names>S</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name><name><surname>Kunz</surname><given-names>WS</given-names></name><article-title>The mechanism of neuroprotection by topiramate in an animal model of epilepsy</article-title><source>Epilepsia</source><year>2004</year><volume>45</volume><fpage>1478</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.13504.x</pub-id><pub-id pub-id-type="pmid">15571505</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>la Marca</surname><given-names>G</given-names></name><name><surname>Fiorini</surname><given-names>P</given-names></name><name><surname>Poggi</surname><given-names>C</given-names></name><name><surname>Cavallaro</surname><given-names>G</given-names></name><name><surname>Malvagia</surname><given-names>S</given-names></name><name><surname>Pellegrini-Giampietro</surname><given-names>DE</given-names></name><name><surname>Guerrini</surname><given-names>R</given-names></name><article-title>Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischaemic encephalopathy</article-title><source>Epilepsia</source><year>2009</year><volume>50</volume><fpage>2355</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02302.x</pub-id><pub-id pub-id-type="pmid">19744111</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Kochanek</surname><given-names>PM</given-names></name><name><surname>Poloyac</surname><given-names>SM</given-names></name><article-title>Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>9</issue><fpage>2196</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000281517.97507.6E</pub-id><pub-id pub-id-type="pmid">17855837</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name><surname>Glier</surname><given-names>C</given-names></name><name><surname>Dzietko</surname><given-names>M</given-names></name><name><surname>Bittigau</surname><given-names>P</given-names></name><name><surname>Jarosz</surname><given-names>B</given-names></name><name><surname>Korobowicz</surname><given-names>E</given-names></name><name><surname>Ikonomidou</surname><given-names>C</given-names></name><article-title>Therapeutic doses of topiramate are not toxic to the developing rat brain</article-title><source>Exp Neurol</source><year>2004</year><volume>187</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.01.025</pub-id><pub-id pub-id-type="pmid">15144866</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>Poggi</surname><given-names>C</given-names></name><name><surname>la Marca</surname><given-names>G</given-names></name><name><surname>Furlanetto</surname><given-names>S</given-names></name><name><surname>Fiorini</surname><given-names>P</given-names></name><name><surname>Cavallaro</surname><given-names>G</given-names></name><name><surname>Plantulli</surname><given-names>A</given-names></name><name><surname>Donzelli</surname><given-names>G</given-names></name><name><surname>Guerrini</surname><given-names>R</given-names></name><article-title>Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><issue>3</issue><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.04.019</pub-id><pub-id pub-id-type="pmid">20553846</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name><surname>Silverstein</surname><given-names>FS</given-names></name><name><surname>Ferriero</surname><given-names>DM</given-names></name><article-title>Off-label use of antiepileptic drugs for the treatment of neonatal seizures</article-title><source>Pediatr Neurol</source><year>2008</year><volume>39</volume><fpage>77</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2008.04.008</pub-id><pub-id pub-id-type="pmid">18639748</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name><surname>Walia</surname><given-names>KS</given-names></name><name><surname>Khan</surname><given-names>EA</given-names></name><name><surname>Ko</surname><given-names>DH</given-names></name><name><surname>Raza</surname><given-names>SS</given-names></name><name><surname>Khan</surname><given-names>YN</given-names></name><article-title>Side effects of antiepileptics-a review</article-title><source>Pain Pract</source><year>2004</year><volume>4</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1111/j.1533-2500.2004.04304.x</pub-id><pub-id pub-id-type="pmid">17173601</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name><surname>Garris</surname><given-names>SS</given-names></name><name><surname>Oles</surname><given-names>KS</given-names></name><article-title>Impact of topiramate on serum bicarbonate concentrations in adults</article-title><source>Ann Pharmacother</source><year>2005</year><volume>39</volume><fpage>424</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1345/aph.1E437</pub-id><pub-id pub-id-type="pmid">15701764</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name><surname>Philippi</surname><given-names>H</given-names></name><name><surname>Boor</surname><given-names>R</given-names></name><name><surname>Reitter</surname><given-names>B</given-names></name><article-title>Topiramate and metabolic acidosis in infants and toddlers</article-title><source>Epilepsia</source><year>2002</year><volume>43</volume><fpage>744</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1046/j.1528-1157.2002.37201.x</pub-id><pub-id pub-id-type="pmid">12102678</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><name><surname>Asconape</surname><given-names>JJ</given-names></name><article-title>Some common issues in the use of antiepileptic drugs</article-title><source>Semin Neurol</source><year>2002</year><volume>22</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1055/s-2002-33046</pub-id><pub-id pub-id-type="pmid">12170391</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><name><surname>Wirrell</surname><given-names>EC</given-names></name><article-title>Neonatal seizures: to treat or not to treat?</article-title><source>Semin Pediatr Neurol</source><year>2005</year><volume>12</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.spen.2005.03.004</pub-id><pub-id pub-id-type="pmid">16114175</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><name><surname>Ritter</surname><given-names>F</given-names></name><name><surname>Glauser</surname><given-names>TA</given-names></name><name><surname>Elterman</surname><given-names>RD</given-names></name><name><surname>Wyllie</surname><given-names>E</given-names></name><article-title>Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group</article-title><source>Epilepsia</source><year>2000</year><volume>41</volume><issue>suppl 1</issue><fpage>S82</fpage><lpage>S85</lpage><pub-id pub-id-type="pmid">10768307</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><name><surname>Biton</surname><given-names>V</given-names></name><name><surname>Montouris</surname><given-names>GD</given-names></name><name><surname>Ritter</surname><given-names>F</given-names></name><name><surname>Riviello</surname><given-names>JJ</given-names></name><name><surname>Reife</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Pledger</surname><given-names>G</given-names></name><article-title>A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1330</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1212/WNL.52.7.1330</pub-id><pub-id pub-id-type="pmid">10227614</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><name><surname>Glauser</surname><given-names>TA</given-names></name><name><surname>Levisohn</surname><given-names>PM</given-names></name><name><surname>Ritter</surname><given-names>F</given-names></name><name><surname>Sachdeo</surname><given-names>RC</given-names></name><article-title>Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group</article-title><source>Epilepsia</source><year>2000</year><volume>41</volume><issue>suppl 1</issue><fpage>S86</fpage><lpage>S90</lpage><pub-id pub-id-type="pmid">10768308</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><name><surname>Battino</surname><given-names>D</given-names></name><name><surname>Croci</surname><given-names>D</given-names></name><name><surname>Rossini</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>S</given-names></name><name><surname>Mamoli</surname><given-names>D</given-names></name><name><surname>Perucca</surname><given-names>E</given-names></name><article-title>Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544040-00005</pub-id><pub-id pub-id-type="pmid">15828853</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><name><surname>Mikaeloff</surname><given-names>Y</given-names></name><name><surname>Rey</surname><given-names>E</given-names></name><name><surname>Soufflet</surname><given-names>C</given-names></name><name><surname>d'Athis</surname><given-names>P</given-names></name><name><surname>Echenne</surname><given-names>B</given-names></name><name><surname>Vall&#x000e9;e</surname><given-names>L</given-names></name><name><surname>Bouhours</surname><given-names>P</given-names></name><name><surname>Grinspan</surname><given-names>A</given-names></name><name><surname>Dulac</surname><given-names>O</given-names></name><name><surname>Pons</surname><given-names>G</given-names></name><name><surname>Chiron</surname><given-names>C</given-names></name><article-title>Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years</article-title><source>Epilepsia</source><year>2004</year><volume>45</volume><fpage>1448</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.65503.x</pub-id><pub-id pub-id-type="pmid">15509246</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><name><surname>Glauser</surname><given-names>TA</given-names></name><name><surname>Miles</surname><given-names>MV</given-names></name><name><surname>Tang</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>P</given-names></name><name><surname>McGee</surname><given-names>K</given-names></name><name><surname>Doose</surname><given-names>DR</given-names></name><article-title>Topiramate pharmacokinetics in infants</article-title><source>Epilepsia</source><year>1999</year><volume>40</volume><fpage>788</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1999.tb00780.x</pub-id><pub-id pub-id-type="pmid">10368080</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><name><surname>Castro Conde</surname><given-names>JR</given-names></name><name><surname>Hern&#x000e1;ndez Borges</surname><given-names>AA</given-names></name><name><surname>Dom&#x000e9;nech Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Gonz&#x000e1;lez Campo</surname><given-names>C</given-names></name><name><surname>Perera Soler</surname><given-names>R</given-names></name><article-title>Midazolam in neonatal seizures with no response to phenobarbital</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>876</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000152891.58694.71</pub-id><pub-id pub-id-type="pmid">15753426</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><name><surname>la Marca</surname><given-names>G</given-names></name><name><surname>Malvagia</surname><given-names>S</given-names></name><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>Fiorini</surname><given-names>P</given-names></name><name><surname>Innocenti</surname><given-names>M</given-names></name><name><surname>Luceri</surname><given-names>F</given-names></name><name><surname>Pieraccini</surname><given-names>G</given-names></name><name><surname>Moneti</surname><given-names>G</given-names></name><name><surname>Francese</surname><given-names>S</given-names></name><name><surname>Dani</surname><given-names>FR</given-names></name><name><surname>Guerrini</surname><given-names>R</given-names></name><article-title>Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method</article-title><source>J Pharm Biomed Anal</source><year>2008</year><volume>48</volume><fpage>1392</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2008.09.025</pub-id><pub-id pub-id-type="pmid">18980824</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>Gozzini</surname><given-names>E</given-names></name><name><surname>Daniotti</surname><given-names>M</given-names></name><name><surname>Pagliai</surname><given-names>F</given-names></name><name><surname>Catarzi</surname><given-names>S</given-names></name><name><surname>Fiorini</surname><given-names>P</given-names></name><article-title>Rescue treatment with terlipressin in different scenarios of refractory hypotension in newborns and infants</article-title><source>Pediatr Crit Care Med</source><year>2011</year><volume>12</volume><issue>6</issue><fpage>e237</fpage><lpage>e241</lpage><pub-id pub-id-type="doi">10.1097/PCC.0b013e3181fe304c</pub-id><pub-id pub-id-type="pmid">21057354</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><name><surname>Palisano</surname><given-names>R</given-names></name><name><surname>Rosenbaum</surname><given-names>P</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Galuppi</surname><given-names>B</given-names></name><article-title>Development and reliability of a system to classify gross motor function in children with cerebral palsy</article-title><source>Dev Med Child Neurol</source><year>1997</year><volume>39</volume><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">9183258</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><name><surname>Romeo</surname><given-names>DM</given-names></name><name><surname>Cioni</surname><given-names>M</given-names></name><name><surname>Scoto</surname><given-names>M</given-names></name><name><surname>Mazzone</surname><given-names>L</given-names></name><name><surname>Palermo</surname><given-names>F</given-names></name><name><surname>Romeo</surname><given-names>MG</given-names></name><article-title>Neuromotor development in infants with cerebral palsy investigated by the Hammersmith Infant Neurological Examination during the first year of age</article-title><source>Eur J Paediatr Neurol</source><year>2008</year><volume>12</volume><issue>1</issue><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2007.05.006</pub-id><pub-id pub-id-type="pmid">17604195</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><name><surname>Dubowitz</surname><given-names>L</given-names></name><name><surname>Ricci</surname><given-names>D</given-names></name><name><surname>Mercuri</surname><given-names>E</given-names></name><article-title>The Dubowitz neurological examination of the full-term newborn</article-title><source>Ment Retard Dev Disabil Res Rev</source><year>2005</year><volume>11</volume><issue>1</issue><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/mrdd.20048</pub-id><pub-id pub-id-type="pmid">15856443</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="book"><name><surname>Bayley</surname><given-names>N</given-names></name><source>Bayley Scales of Infant and Toddler Development III</source><year>2005</year><publisher-name>Oxford. UK: Psychological Corporation</publisher-name></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><name><surname>Ricci</surname><given-names>D</given-names></name><name><surname>Cesarini</surname><given-names>L</given-names></name><name><surname>Groppo</surname><given-names>M</given-names></name><name><surname>De Carli</surname><given-names>A</given-names></name><name><surname>Gallini</surname><given-names>F</given-names></name><name><surname>Serrao</surname><given-names>F</given-names></name><name><surname>Fumagalli</surname><given-names>M</given-names></name><name><surname>Cowan</surname><given-names>F</given-names></name><name><surname>Ramenghi</surname><given-names>LA</given-names></name><name><surname>Anker</surname><given-names>S</given-names></name><name><surname>Mercuri</surname><given-names>E</given-names></name><name><surname>Mosca</surname><given-names>F</given-names></name><article-title>Early assessment of visual function in full term newborns</article-title><source>Early Hum Dev</source><year>2008</year><volume>84</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.earlhumdev.2007.03.010</pub-id><pub-id pub-id-type="pmid">17513071</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><name><surname>Ricci</surname><given-names>D</given-names></name><name><surname>Cesarini</surname><given-names>L</given-names></name><name><surname>Gallini</surname><given-names>F</given-names></name><name><surname>Serrao</surname><given-names>F</given-names></name><name><surname>Leone</surname><given-names>D</given-names></name><name><surname>Baranello</surname><given-names>G</given-names></name><name><surname>Cota</surname><given-names>F</given-names></name><name><surname>Pane</surname><given-names>M</given-names></name><name><surname>Brogna</surname><given-names>C</given-names></name><name><surname>De Rose</surname><given-names>P</given-names></name><name><surname>Vasco</surname><given-names>G</given-names></name><name><surname>Alfieri</surname><given-names>P</given-names></name><name><surname>Staccioli</surname><given-names>S</given-names></name><name><surname>Romeo</surname><given-names>DM</given-names></name><name><surname>Tinelli</surname><given-names>F</given-names></name><name><surname>Molle</surname><given-names>F</given-names></name><name><surname>Lepore</surname><given-names>D</given-names></name><name><surname>Baldascino</surname><given-names>A</given-names></name><name><surname>Ramenghi</surname><given-names>LA</given-names></name><name><surname>Torrioli</surname><given-names>MG</given-names></name><name><surname>Romagnoli</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>F</given-names></name><name><surname>Atkinson</surname><given-names>J</given-names></name><name><surname>Cioni</surname><given-names>G</given-names></name><name><surname>Mercuri</surname><given-names>E</given-names></name><article-title>Cortical visual function in preterm infants in the first year</article-title><source>J Pediatr</source><year>2010</year><volume>156</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2009.10.042</pub-id><pub-id pub-id-type="pmid">20056237</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><name><surname>Sarnat</surname><given-names>HB</given-names></name><name><surname>Sarnat</surname><given-names>MS</given-names></name><article-title>Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study</article-title><source>Arch Neurol</source><year>1976</year><volume>33</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1001/archneur.1976.00500100030012</pub-id><pub-id pub-id-type="pmid">987769</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><name><surname>al Naqeeb</surname><given-names>N</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Cowan</surname><given-names>FM</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><article-title>Assessment of neonatal encephalopathy by amplitude-integrated electroencephalography</article-title><source>Pediatrics</source><year>1999</year><volume>103</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1542/peds.103.6.1263</pub-id><pub-id pub-id-type="pmid">10353940</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><name><surname>Shalak</surname><given-names>LF</given-names></name><name><surname>Laptook</surname><given-names>AR</given-names></name><name><surname>Velaphi</surname><given-names>SC</given-names></name><name><surname>Perlman</surname><given-names>JM</given-names></name><article-title>Amplitude-integrated electroencephalography coupled with an early neurologic examination enhances prediction of term infants at risk for persistent encephalopathy</article-title><source>Pediatrics</source><year>2003</year><volume>111</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1542/peds.111.2.351</pub-id><pub-id pub-id-type="pmid">12563063</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><name><surname>Hellstr&#x000f6;m-Westas</surname><given-names>L</given-names></name><name><surname>Ros&#x000e9;n</surname><given-names>I</given-names></name><name><surname>Svenningsen</surname><given-names>NW</given-names></name><article-title>Predictive value of early continuous amplitude integrated EEG recordings on outcome after severe birth asphyxia in full term infants</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>1995</year><volume>72</volume><fpage>F34</fpage><lpage>F38</lpage><pub-id pub-id-type="doi">10.1136/fn.72.1.F34</pub-id><pub-id pub-id-type="pmid">7743282</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><name><surname>Spitzmiller</surname><given-names>RE</given-names></name><name><surname>Phillips</surname><given-names>T</given-names></name><name><surname>Meinzen-Derr</surname><given-names>J</given-names></name><name><surname>Hoath</surname><given-names>SB</given-names></name><article-title>Amplitude-integrated EEG is useful in predicting neurodevelopmental outcome in full-term infants with hypoxic-ischemic encephalopathy: a meta-analysis</article-title><source>J Child Neurol</source><year>2007</year><volume>22</volume><fpage>1069</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1177/0883073807306258</pub-id><pub-id pub-id-type="pmid">17890403</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Hellstr&#x000f6;m-Westas</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>de Vries</surname><given-names>LS</given-names></name><article-title>Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-2938</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="book"><name><surname>Glantz</surname><given-names>SA</given-names></name><source>Primer of Biostatistics</source><year>2005</year><edition>6</edition><publisher-name>New York: McGraw-Hill</publisher-name></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="book"><name><surname>Volpe</surname><given-names>JJ</given-names></name><person-group person-group-type="editor">Volpe JJ</person-group><article-title>Hypoxic-Ischemic Encephalopathy: Clinical Aspects</article-title><source>Neurology of the newborn</source><year>2008</year><edition>5</edition><publisher-name>Philadelphia, PA: Saunders Elsevier</publisher-name><fpage>400</fpage><lpage>480</lpage></mixed-citation></ref></ref-list></back></article>